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n ACh receptor nicotinic acetyl choline receptor 
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Rf  retention factor 
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1 Introduction 
 
1.1 Natural products in drug discovery 
 
Plants have always been a good source for (small molecule) drugs, since they produce a wide 
range of bioactive primary and secondary metabolites. Conservatively estimated, natural 
products (NPs) and products derived thereof including semi-synthetic drugs and natural 
product-mimetics, still account for approximately 30 % of all newly approved drugs between 
1981 and 2006 (Fig. 1; Harvey et al., 2010; Newman, 2008; Potterat et al., 2008). 
Furthermore, the impact of natural products on our knowledge about basic biological 
processes can be recognized in the great variety of drug targets that are named after 
compounds from natural origin like µ-(morphine)-opioid, nicotinic and muscarinic acetyl 
choline-, cannabinoid-, or kainate receptor. 
 
 
 
 
Figure 1. Natural products in drug discovery. The pie chart displays all new chemical entities approved as drugs 
between 1981 and 2006.  “B” Biological; usually a large (>45 residues) peptide or protein either isolated from an 
organism/cell line or produced by biotechnological means in a surrogate host. “N” Natural product. “ND” 
Derived from a natural product and is usually a semisynthetic modification. “S” Totally synthetic drug, often 
found by random screening/modification of an existing agent. “S*” Made by total synthesis, but the 
pharmacophore is/was from a natural product. “V” Vaccine. “NM” Natural product mimic (Newman and Cragg, 
2007). 
 
The discovery of new drugs from natural sources mainly focuses on anti-cancer or anti-
infective/-microbial activities and a comparably smaller number of studies deals with the 
effects of natural compounds on the central nervous system (CNS) (Butler, 2008). However, 
basic knowledge in neuroscience was primarily gained by studies of CNS-active natural 
products, and they still remain crucial research tools in the field of neuroscience as well as 
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viable therapeutic targets for disease of the CNS. Moreover, such disorders are not limited to 
a small group of patients but affect a great number of the worldwide population (Tab. 1.) 
 
Disorder Population (%) references 
Alzheimer’s Disease 13.0 % older 65y (Castellani et al.) 
Anxiety 16.6 % (Somers et al., 2006) 
Depression/mood disorders 5.3 % US (Gelenberg, 2010) 
Epilepsy 0.5 - 1.0 % (WHO, 2005) 
Sleep disorders 30,00% (Roth, 2007) 
Other mental disorders 13.0 % (WHO, 2004) 
Table 1. Worldwide prevalence of common mental health disorders  
 
As can be seen in Table 1, sleep and anxiety disorders are among the most prevalent mental 
disorders. In western countries, several synthetic drug classes are applied in the treatment of 
these diseases, including histamine-1 receptor (H1)-antagonist for sedation, antidepressants 
(e.g. serotonin/norepinephrine reuptake inhibitors) for anxiolysis or benzodiazepines for both. 
The use of CAM is equally common; many people even favor the use of alternative treatment 
strategies over the use of synthetic derivatives since the risk of unwanted side effects is 
considered a lower one (van der Watt et al., 2008; Sarris and Byrne, [Online early access]). 
One molecular target both, anxiety and insomnia, share is the γ-amino butyric acid (GABA) 
type A (GABAA) receptor. Thus, in the following chapter, GABAergic neurotransmission will 
be elucidated focusing on the GABAA receptor  
 
 
1.2 γ-Aminobutyric acid (GABA) 
 
From the many targets for CNS drugs, the GABAergic system is of crucial importance, since 
GABA is the major inhibitory neurotransmitter in the mammalian brain (Somogyi et al., 
1998). GABA is counteracted by glutamate, which is responsible for the majority of 
excitatory neurotransmission, and balance of GABAergic and glutamergic signals is vital for 
the functioning of the CNS. Thus, an imbalance of these two neurotransmitter systems is 
probably involved in many if not all CNS disorders to some extent, making the GABAergic 
system a viable target for CNS drugs (Olsen, 2002). This might also be due to the fact, that 
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most of the interneurons found in the CNS, which regulate the activity of other 
neurotransmitter systems, are GABAergic (Mody and Pearce, 2004).  
Nonetheless, manipulation of the GABAergic neurotransmission is more commonly related to 
a distinct set of disorders like epilepsy (Galanopoulou, 2010; Macdonald et al., 2010), anxiety 
disorders (Kalueff and Nutt, 2007; Durant et al., 2010), and insomnia (Ebert et al., 2006; 
Winsky-Sommerer, 2009). But there is evidence for involvement of this receptor in 
schizophrenia and other neuropsychiatric disorders (Lewis et al., 2008; Möhler, 2009; 
Vinkers et al., 2010) or in the development of tolerance and addiction (Enoch, 2008; Tan et 
al., 2010). Furthermore, it may also proof useful to target GABAA receptors in the treatment 
of neuropathic pain (Enna and McCarson, 2006; Munro et al., 2009; Zeilhofer et al., 2009). 
 
 
 
Figure 2. The GABAergic synapse. GABA is synthesized from glutamate by GAD, stored in vesicles and 
transported to the presynaptic membrane for release in the synapse, where it activates the GABA receptors type 
A and B. It is rapidly taken up through GATs, stored in vesicles again or degraded by GABA-T and SSADH. 
GAD: glutamate dehydrogenase VGAT: vesicular GABA transporter, GAT: GABA transporter, GABA-T: 
GABA transaminase, SSADH: succinic semi-aldehyde dehydrogenase (Owens and Kriegstein, 2002). 
 
GABA itself is derived enzymatically from glutamate by glutamate decarboxylase (GAD), 
and 2 subtypes of this enzyme are known so far (GAD65 and GAD67). It is degraded into α-
ketoglutarate or succinic acid through GABA-Transaminase (GABA-T) and succinic semi-
aldehyde dehydrogenase (SSADH), respectively before it enters the Krebs cycle. This enzyme 
machinery is also referred to as the GABA shunt (Hassel et al., 1998; Yogeeswari et al., 
2005). GABA is stored in small vesicles, in which it is transported through the vesicular 
GABA transporter (VGAT). GABA is released into the synaptic cleft by fusion of the small 
vesicles to the presynaptic membrane, where it can bind to its target receptors. Shortly 
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thereafter it is taken up again in the pre-synapse or in surrounding glia cells by GABA 
transporters (GAT 1-3 and the low affinity transporter BGT 1), where it is stored in vesicles 
or degraded through GABA-T and SSADH (Owens and Kriegstein, 2002) as depicted in 
figure  2, p. 3. 
There are two types of GABA receptors: (1) GABAA and GABAA-ρ receptors, latter also 
referred to as GABAC receptors, are ligand gated ion channels and thus responsible for fast 
inhibition of neurotransmission (Mody and Pearce, 2004). (2) GABAB receptors are G-protein 
coupled receptors (GPCRs). These metabotropic receptors mainly influence K+ and Ca2+ 
channels, as well as second messenger systems. This again results in a decrease of 
neurotransmission, albeit slower as the inhibitory signals mediated by GABAA receptors 
(Bowery et al., 2002).  
 
 
1.2.1 The GABAA receptor 
 
The binding of GABA to GABAA receptors leads to conformational changes of the 
channel/receptor complex. These allow the channel to open and chloride as well as 
bicarbonate anions can influx the cell following their potential gradient. The increased amount 
of negative charge in the intracellular space hyperpolarizes the membrane. This results in an 
inhibitory postsynaptic potential that decreases the possibility of neurotransmission. This 
process is balanced by glutamate and finally the sum of excitatory and inhibitory signals 
determines if the postsynaptic neuron transmits a signal (D'Hulst et al., 2009). Although most 
of the GABAA receptors can be found in the synapse (post- and presynaptic), there are peri- 
and extrasynaptic receptors as well. While postsynaptically assembled receptors mediate 
phasic inhibition, extrasynaptic receptors seem to be responsible for tonic inhibition of 
neurotransmission (Mody and Pearce, 2004).  
 
 
 
1.2.1.1 GABAA receptor structure 
 
GABAA receptors are Cys-Loop pentameric ligand gated ion channels (LGIC) and closely 
related to nicotinic acetyl choline (nACh), 5-hydrosytryptamine type 3 (5-HT3) and glycine 
receptors. Both, the C- and the N-terminus stretch out in the extracellular room, with a highly 
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conserved Cys-loop in the extracellular domain of the N-terminus. Generally, each of the 5 
subunits consists of four transmembrane (TM) domains. They form a central pore in which 
the four TMs2 build the inner wall of this pore, which functions as the ion channel. The 
transmembrane domains TM3 and TM4 are linked through a large intracellular loop, which is 
responsible for most of the interactions between the receptor and the cytosol as depicted in 
figure 3A (Jacob et al., 2008).  
Although the crystal structure of the GABAA receptor could not be solved so far, there are 
computational homology models that derive its presumed structure using other proteins of the 
Cys-loop pentameric receptor superfamily based on the fact, that all these receptors share at 
least 30 % sequence similarity. This includes the nACh receptor of the marbled electric ray 
(Torpedo marmorata) which is depicted in figure 3B (Unwin, 2005). 
 
 
Figure 3. Structure of Cys-Loop pentameric ligand gated ion channels. A. Each of the five subunits consists of 4 
transmembrane domains, whereby TM3 and TM4 are linked through a large intracellular loop. Both, the N- and 
C-terminus, are situated in the extracellular room. (Jacob et al., 2008). B. Top view of a αnβnγn GABAA receptor 
channel. The 5 TM2s, here indicated as helix II build the inner wall of the pore (Ernst et al., 2005) C. 4 Ǻ crystal 
structure of the nACh receptor isolated from Torpedo marmorata (Unwin, 2005) (left). The transmembrane 
domains are enclosed in the green box. 
 
Furthermore, the soluble acetylcholine binding protein from the mollusk Lymnaea stagnalis 
(Brejc et al., 2001) or the water soluble portion of the muscle nACh receptor (Dellisanti et al., 
C 
A 
B
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2007; Chen, 2010) were used for homology models. There is good scientific evidence, that 
most functional GABAA receptors are build from 3 different types of subunits and that these 3 
subunit-types are arranged alternately. In figure 3C, p. 5 (Ernst et al., 2005), the top view of a 
representative αβγ-recpetor, is displayed in its typical α-β-α-β-γ arrangement (Tretter et al., 
1997; Baumann et al., 2002; Minier and Sigel, 2004). Each interface between the different 
subunits is formed by contacts between the membrane spanning helices II (TM2s), as well as 
by contacts of helix I (TM1) of the minus side with helix III (TM3) of the plus side in two 
connected subunits (Ernst et al., 2005). 
 
 
     
1.2.1.2 Subunits and subtypes  
 
GABAA receptors are widely distributed within the CNS. They show a considerable 
heterogeneity arising from the existence of 19 different subunits identified in the human 
genome: α1-6, β1-3, γ1-3, δ, ε, ρ1-3, θ and π (Simon et al., 2004), whereby various splice variants 
add to this variety e.g. γ2S and γ2L (Whiting et al., 1990). Since the GABAA receptor is formed 
from 5 subunits, this would theoretically allow the existence of some thousand different 
receptor subtypes, whereas only a few combinations have been conclusively identified in situ 
(Olsen and Sieghart, 2008). In general, α1-6, β1-3, and γ2 are considered the major GABAA 
receptor subunits in the mammalian brain, while the abundance of γ1, γ3, θ, ε, π and ρ1-3  is 
rather low and/or scientific investigations on native receptors containing these subunits is still 
rare (Olsen and Sieghart, 2009). However, most of the native receptors are made up from two 
α, two β and one γ subunit. The most abundant receptor subtype is α1β2γ2, which represent 
around 60 % of all GABAA receptors in the mammalian brain, followed by α2β3γ2 (15-20 %) 
and α3βnγ2 (10 to 15 %). α4βnδ, α5βnγ2 as well as α6βnδ receptors each occur to less than 5 % in 
the mammalian brain (Sieghart and Sperk, 2002; Moehler, 2006).  
Different GABAA receptor subtypes exert different pharmacological profiles as extensively 
reviewed by Olsen and Sieghart (2008, 2009). In addition, these subtypes differ in their 
distribution pattern throughout the brain or even in their localization in a single neuron 
(Wisden et al., 1992; Korpi et al., 2002; Sieghart and Sperk, 2002). Thus, the different 
GABAA receptor subtypes are thought to be highly specialized for a specific neuronal circuit 
and thus for different CNS disorders.  
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Receptor pharmacology based on subunits 
That the pharmacological profile of a receptor subtype depends on the subunits it is co-
assembled from was convincingly shown for the first time through altered reaction of α-
subunit knock-in mutated mice to diazepam. It was shown that the mutation of α1 led to the 
loss of diazepam mediated sedation (Rudolph et al., 1999). In several subsequent studies it 
was found that different α-subunits are responsible for different pharmacological effects. 
Thus, while α1 subunits are mostly responsible for sedation (McKernan et al., 2000), α2 
mediates the anxiolytic effects of diazepam (Löw et al., 2000), which seems to be valid for α3 
as well (Atack et al., 2005; Dias et al., 2005). Furthermore, α3 and α5 are connected to 
psychiatric disorders (Yee et al., 2004; Hauser et al., 2005). Receptors containing an α5 
subunit are also involved in learning and memory (Martin et al., 2009), which is enhanced 
when this subunit is inactivated or α5 selective inverse agonist are applied (Crestani et al., 
2002; Collinson et al., 2006; Dawson et al., 2006; Prut et al., 2010)  
Since both, α4 and α6 subunits, are in-sensitive to diazepam, such experiments could not be 
carried out for these two α-subunits. However, they are often co-assembled with the δ-
subunits in extra- or perisynaptic receptors (Nusser et al., 1998; Peng et al., 2002; Wei et al., 
2003). These receptors exhibit a strongly different pharmacological profile (higher affinity for 
GABA and other drugs than BZs, lower desensitization rate) and are thought to be responsible 
for most of the tonic inhibition in the CNS (Caraiscos et al., 2004; Mody and Pearce, 2004; 
Farrant and Nusser, 2005).  
Following the studies on the diazepam-sensitive α-subunits, other subunits were also 
investigated for distinct pharmacological profiles. In general, most β-subunit incorporating 
receptors contain β2, followed by β3 > β1 (Sur et al., 2001). β-subunits are not as well 
characterized concerning subunit-specific effects, although a variety of β-selective substances 
has been found e.g. the anticonvulsant loreclezole (Wingrove et al., 1994). Additionally, the 
GABAergic effects of alcohol seem to be majorly mediated via the β-subunits as well 
(Wallner et al., 2003). Mutations in β2 and β3 subunits showed, that the sedative actions of 
etomidate are mediated through β2 (Reynolds et al., 2003), the anesthetic/immobilizing 
actions through β3 subunits (Jurd et al., 2003). Moreover, there is evidence for involvement of 
β3-containing receptor subtypes in alcohol tolerance and withdrawal (Sanchis-Segura et al., 
2007) as well as epilepsy (Homanics et al., 1997). 
From γ-subunits it is known, that they are crucial for the activity of benzodiazepines. BZs 
display a somewhat different pharmacology on subtypes incorporating γ2 (most sensitive) 
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compared to γ1 (low affinity) and γ3, where classical BZs like diazepam show no binding 
compared to e.g. z-drugs like zaleplone or zopiclone (Sieghart, 1995; Hevers and Luddens, 
1998; Khom et al., 2006). The γ2-subunit is present in 75-80 % of all GABAA receptors. It can 
be substituted through γ1 and γ3, as well as δ or ε, while the θ and π are only barely 
characterized (Olsen and Sieghart, 2008). 
 
 
1.2.1.3 GABAA receptor dynamics  
 
The life cycle of the GABAA receptor is highly regulated and can be modified at various 
stages beginning with expression and assembly of the different subunits to functional 
receptors in the endoplasmatic reticulum. Although there is increasing evidence for a wide 
range of proteins interacting with the GABAA receptor (Fig. 4, p. 9), two of them are strongly 
connected to GABAA receptor dynamics, the GABA receptor associated protein (GABARAP) 
and gephyrin  (Jacob et al., 2008).  
Gephyrin was the first protein directly associated with GABAA receptors and it is tightly co-
localized with them in the post-synaptic membrane (Kneussel and Betz, 2000; Lüscher and 
Keller, 2004). It anchors the receptors in the membrane, thus being responsible for 
stabilization and clustering. Inhibition of gephyrin expression leads to a total loss of α2 and γ2 
subunits in hippocampal cultures (Kneussel, 2002) and a dramatic decrease in GABAA 
receptor clustering was observed in gephyrin knock-out mice (Essrich et al., 1998). The 
clusters that could form in absence of gephyrin showed high mobility and receptors diffused 
all over the neuronal membrane instead of accumulating at the synapse (Jacob et al., 2005). 
GABARAP seems to be an adaptor protein which selectively interacts with the γ2-subunits of 
assembled receptors and can bind to microtubules as well as the anchoring protein gephyrin or 
the membrane fusion factor NSF (N-ethylmaleimide-sensitive fusion protein). Thus, 
GABARAP plays a major role in trafficking and clustering of γ-subunit containing receptors 
(Chen and Olsen, 2007). Knock-out mice lacking GABARAP nonetheless display normal 
phenotypes, thus indicating that other proteins can substitute for GABARAP (O'Sullivan et 
al., 2005).  
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Figure 4. GABAA receptor dynamics.  A range of proteins, as indicated in the figure, can influence successful 
expression and assembly of functional GABAA receptors at the cell surface and their internalization, often 
interacting with specific subunits (Chen and Olsen, 2007). GODZ: Golgi-specific DHHC zinc finger protein, 
BIG2: Brefeldin A-inhibited GDP/GTP exchange factor 2, Plic-1: proteins linking IAP (CD47) to cytoskeleton-
1, PRIP: PLC-related catalytically inactive protein, HAP: huntingtin-associated protein, GRIP: glutamate 
receptor interacting protein, GRIF-1: GABAA receptor interacting factor-1.  
 
 
Internalization of GABAA receptors into clathrin coated vesicles is mediated by adaptor 
protein 2 (AP-2) (Kittler et al., 2002; Smith et al., 2008) and such internalized GABAA 
receptors are transferred to the intracellular space. Here they await their recycling near the 
postsynaptic site, bound to gephyrin (Van Rijnsoever et al., 2005) or are degraded in the 
endosomal system (Kittler and Moss, 2003). Still, many mechanisms of receptor dynamics 
remain to be elucidated. 
 
 
1.2.1.4 GABAA receptor ligands  
 
Actually, GABAA receptor pharmacology began in the 1970ies, when the convulsant 
bicuculline was found to inhibit certain inhibitory actions of GABA (Curtis et al., 1971), 
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approximately 20 years after GABA was initially detected in the brain (Awapara, 1950). 
Subsequently the essential role of GABA in inhibitory neurotransmission and its target 
receptors were investigated and a wide range of GABAA receptor ligands was discovered 
(Fig. 5).  
GABA itself interacts with a binding site situated on the interface between α and β subunits. 
This site is highly conserved in all subunits, albeit different subunits show variations in the 
potency of GABA binding (Ebert et al., 1997). Next to GABA some other compounds 
mediate their effects through this binding site like the agonists muscimol, isoguvacine, the 
partial agonist gaboxadol (Krogsgaard-Larsen et al., 1977) and the aforementioned 
bicuculline. Additionally, there are some non-competitive antagonist, which exert their 
activity on a binding site inside of the channel pore (Ffrench-Constant et al., 1993), like 
picrotoxin(in) (PTX) and t-butylbicyclophosphorothionate (TBPS) as well as pentylentetrazol 
(PTZ). The clinical relevance of these compounds is low, but especially the competitive and 
non-competitive antagonists are often used to assess anticonvulsive activity of drugs in animal 
models. 
 
 
 
Figure 5. Endogenous ligands and drugs for the GABAA receptor. The PTX binding site, not depicted in this 
figure, is believed to be situated inside the channel pore (Harrison, 2007).   
 
However, a range of clinically important drugs target the GABAA receptor and they are used 
in the treatment of anxiety, epilepsy and insomnia, as well as for induction and maintenance 
of anesthesia and to ease alcohol withdrawal (Sieghart, 1995; Korpi et al., 2002). From all the 
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drugs targeting the GABAA receptor, the benzodiazepines (BZs) are probably the most 
commonly known ligands, since they are often prescribed in the treatment of anxiety and 
sleep disorders. 
 
Benzodiazepines 
Generally, the binding site for BZs is distinct from the GABA binding site and situated 
between α and γ-subunits. Although the β-subunit is needed for functional receptors, it does 
not greatly influence the receptors sensitivity to BZs (Hadingham et al., 1993). Moreover, 
differences in the pharmacological activities of BZs are mostly mediated via the α-subunit, as 
already mentioned before. 
Benzodiazepines are used against insomnia since the 1960ies and for almost 10 years 
Valium® was the most prescribed drug worldwide (D'Hulst et al., 2009). They superseded the 
barbiturates as hypnotic-sedative drugs due to their more favorable pharmacological profile. 
BZs are positive allosteric modulators and can not directly activate GABAA receptors, 
compared to barbiturates and thus are not as easily overdosed (Korpi et al., 2002). Next to 
their sedative effects, BZs have a very broad range of activities and depending on their 
plasma-half life they are used for different disorders. Short- and intermediate-half life BZs are 
primarily used in the treatment of insomnia (e.g. lorazepam or temazepam). BZs with a longer 
plasma half-life are preferentially used to treat anxiety disorders especially generalized 
anxiety disorder (GAD) or panic disorders e.g. diazepam (WHO, 2009). Their anticonvulsant 
activity also makes BZs viable drugs in the therapy of epilepsy e.g. clobazam (Brodie, 2010).  
Although the use of BZs is comparably save, they can generate a variety of side effects like 
fatigue, somnolence, drowsiness, ataxia, lethargy, sedation, involuntary muscle relaxation and 
worse, amnesia, tolerance, dependence and withdrawal symptoms (Lader, 2008). This of 
course limits their clinical use especially in the treatment of chronic disorders like anxiety or 
insomnia (WHO, 2009). Nowadays the BZs are often replaced by non-benzodiazepines, also 
referred to as the Z-drugs (zopiclone, zolpidem and zaleplone). These drugs, albeit 
structurally different, also interact with the BZ binding site. Still, their clinical advantage over 
BZs is not convincingly proven (Siriwardena et al., 2008). 
There is also evidence for naturally occurring BZs (Sangameswaran et al., 1986), so called 
endozepines that are biosynthesized in humans probably through the intestinal flora (Baraldi 
et al., 2009) or ingested with food, since they also have been found in various (edible) plants 
(Medina et al., 1989).   
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Barbiturates 
They have long been used as sedative and anxiolytic agents but due to their unfavorable 
pharmacological profile now have only limited use e.g. in the treatment of generalized 
seizures or to induce anesthesia. Among the barbiturates still on the market are thiopental, 
pento-, and phenobarbital. As already mentioned, barbiturates can not only modulate GABA 
activity but directly activate the GABAA receptor which makes them a more potent but also a 
more dangerous drug class compared to BZs.   
 
Non-volatile and volatile anesthetics 
Many anesthetic drugs exert their activity via the GABAA receptor; among them are the above 
mentioned barbiturates as well as etomidate, propofol and volatile anesthetics like enflurane 
or halothane (Korpi et al., 2002). While propofol and etomidate are used to induce anesthesia 
(Li et al., 2010a), the volatile anesthetics like en- or isoflurane are used for anesthesia 
maintenance. They exert their activity at least partly over GABAA receptors (Jones et al., 
1992), but the exact mechanism of their action or the putative binding sites need further 
characterization (Solt and Forman, 2007; Li et al., 2010a).  
 
Neurosteroids 
Compared to the above mentioned drugs, neurosteroids are endogenous ligands of the 
GABAA receptor. It was already found in the 1940ies, that certain pregnane steroids have 
strong sedative and anesthetic effects (Selye, 1941). Neurosteroids (5α,3α and 5β,3α-
THPROG, tetrahydroprogesterone) are biosynthesized from progesterone and can either act as 
positive allosteric modulators in low (nM) concentrations or as direct agonists in higher (more 
than 100 nM) concentrations (Lambert et al., 1990). They not only act as sedative and 
anesthetic agents, but have anxiolytic and anticonvulsant activity (Mihalek et al., 1999). 
There is now increasing evidence that these steroidal compounds are synthesized in situ in the 
CNS and act from the intracellular compartment on the receptors, exerting paracrine and 
autocrine effects (Lambert et al., 2009).  
Several binding domains could be identified so far, which seem to be located at the α and the 
β subunit, but are distinct from all other binding sites found at the GABAA receptor (Hosie et 
al., 2007; Hosie et al., 2009; Ator et al., 2010). Neurosteroids preferentially bind to δ-subunit 
containing receptor subtypes or at least δ-/- mice are devoid of the normally observed 
neurosteroidal effects and the abundance of δ-subunit containing receptors is probably highly 
regulated by neurosteroid levels (Herd et al., 2007). In their recent publication, Rupprecht and 
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co-workers (Rupprecht et al., 2009) targeted the neurosteroids by applying the translocator 
protein (18 kD)-ligand XBD173, which promoted the synthesis of neurosteroids and thus 
exhibited anti-panic activity in humans. Thus neurosteroid-targeting drugs or neurosteroid-
analogues will most likely add to the variety of GABAA receptor-interacting drugs for therapy 
of CNS disorders in the near future. 
 
 
1.2.2 The GABAB receptor 
 
The discovery of GABAB receptors by Bowery et al. (1980) was due to their insensitivity to 
bicuculline, and although activated by GABA, the receptors actions were not mediated by 
influx of Cl-. Moreover, the muscle relaxant baclofen binds specifically to these receptors, and 
is the only GABAB receptor modulator used in clinics so far. 
Successively, it was found that, in contrast to GABAA ion channels, GABAB receptors are 
metabotropic receptors and like all GPCRs, both of the two subunits consist of seven 
transmembrane domains (Millar and Newton, 2010). The GABAB receptor itself is an 
inhibitory Gi/o receptor. The Gαi subunit blocks cAMP formation trough inhibition of 
adenylate cyclase and thus decreases the cell’s conductance for Ca2+ and influences many 
intracellular signaling pathways. The Gβγ protein binds to voltage gated K+ (Kir3) channel and 
finally hyperpolarizes the neuronal membrane.  Both pathways lead to a inhibition of 
neurotransmission and, more importantly, to adaptations and changes in receptor expression 
(Padgett and Slesinger, 2010). Remarkably, the GABAB receptor was also the first GPCR 
where it was convincingly shown that heterodimerization can be necessary for the building of 
a functional receptor (Jones et al., 1998). So far, only two GABAB receptor subunits could be 
found GABAB1 and GABAB2, whereby GABAB1 exists in two isoforms (GABAB1a and 
GABABB1b). The heterodimeric GABAB receptor is assembled from a B1 and a B2 subunit but 
it is possible that functional homodimeric GABAB1 receptors exists (Bettler et al., 2004; 
Gassmann et al., 2004; Villemure et al., 2005).  
Immunolabeling studies show that GABAB subunits are present in both, GABAergic and 
glutamergic pre- and postsynaptic sites, and can be found outside of the synapse as well. And 
it is believed that there is a strong interaction between GABAB and glutamergic signaling 
leading to changes in synaptic plasticity and to inhibition of action potential generation via 
GABAB  (Chalifoux and Carter, 2010). 
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As recently reviewed, a range of proteins responsible for expression, trafficking, cell-surface 
expression and internalization of GABAB receptors have been found (Bettler and Tiao, 2006) 
e.g. Coat protein complex 1 (COP1), msec7-1, the two transcription factors ATF4/CREB 
(Vernon et al., 2001) and CHOP (Sauter et al., 2005), or Marlin-1, a RNA binding protein 
(Vidal et al., 2007). Interestingly, GABAB1 subunits can interact with the GABAA receptor γ2-
subunit and this interaction leads to an increase in agonist-induced internalization of the 
GABAB receptor (Bettler and Tiao, 2006).  
GABAB receptor agonists and modulators could proof useful in the treatment of addiction, 
depression and gastro-esophageal reflux disease (Cryan and Slattery, 2010; Lehmann et al., 
2010; Tyacke et al., 2010). 
 
 
1.3 Natural compounds as GABAA receptor ligands 
 
A vast variety of natural compounds, mostly but not solely derived from plants, have already 
been investigated for their activity on GABAergic targets (Johnston et al., 2006b). Next to 
substances acting as GABA-T inhibitors e.g. gastrodin (An et al., 2003) triterpene acids  
(Awad et al., 2009b) or coumarins (Choi et al., 2005); and GAT-inhibitoires (Zhao et al., 
2010), many natural products exert their effects via interaction with the GABAA receptor. 
 
Alkaloids  
The alkaloid bicuculline (Fig. 6A, p. 15) was the first compound recognized as GABAA 
receptor-affecting natural compounds (see chapter 1.2.1.4, p. 9), which can be found in 
Corydalis or other plant species. Other prominent representatives are the bicuculline-related 
compound (+)hydrastine (Huang and Johnston, 1990) or the agonist muscimol (Fig. 6B, p. 15) 
isolated from Amanita muscaria (Johnston et al., 1968). All three compounds directly interact 
with the GABA binding site. Securinine - an indolizidine alkaloid isolated from Flueggea 
suffruticosa (Pall.) Baill. - and related components were found to function as GABAA receptor 
antagonists, probably also due to direct interaction with the GABA binding site (Beutler et al., 
1985).  
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Figure 6. Examples for alkaloids, flavonoids and fragrant compounds affecting the GABAA receptor. (A) 
Bicucculine. (B) Muscimol. (C) Piperine. (D) Apigenin. (E) Cis-jasmone. 
 
Furthermore, the diterpene-alkaloid songorine, found in Aconitum species, acts as a GABAA 
receptor antagonist (Zhao et al., 2003), and the purine alkaloids theobromine and theophylline 
even displayed negative modulatory effects when tested in a functional assay (Hossain et al., 
2003). More recently, the pungent principle of Piper sp. - piperine (Fig. 6C) - was found to 
enhance IGABA to some extent (Zaugg et al., 2010). 
 
Fatty acids 
Linoleic acid and its hydro-peroxide displayed inhibitory activity on GABAA receptor 
channels in a functional assay using whole rat brain mRNA injected in X. laevis oocytes 
(Aoshima, 1996). Another fatty acid, docosahexaenoic acid, which can be found in high 
amounts in fish oil or is produced by certain algae, was also found to inhibit IGABA (Nabekura 
et al., 1998). Both, linoleic and docosahexaenoic acid are considered essential fatty acids, but 
what the above mentioned observations mean in context to physiological processes in the 
CNS still needs further elucidation. 
 
Flavonoids and related compounds  
Flavonoids are known for an immense range of bioactivities (Middleton jr. et al., 2000; 
Andersen, 2006; de Pascual-Teresa et al.) and many of them have already been investigated 
for their activity on GABAA receptors or their affinity to the BZ binding site, with 
miscellaneous results.  
For example, the biflavonoid amentoflavone displays high affinity for the BZ binding site 
(Nielsen et al., 1988; Baureithel et al., 1997) and is a negative allosteric modulator of GABAA 
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receptors in the functional assay (Hanrahan et al., 2003). The actions of apigenin (Fig. 6D, p. 
15) on the GABAA receptor are more complex since it binds with high affinity to the BZ 
binding site, is a negative allosteric modulator co-applied with GABA. Interestingly, it 
enhances the positive effects of diazepam on IGABA at least in vitro. Upon this finding the term 
of “second order modulator” was created (Campbell et al., 2004).  
Methylated and methoxylated flavonoids like 6-methylflavanone (Hall et al., 2005), 6-
methylflavone (Ai et al., 1997; Hall et al., 2004b), 6-methyl-apigenin (Wasowski et al., 2002) 
or hispidulin (Kavvadias et al., 2004) exert highest activity on the GABAA receptor so far. 
Only recently, a range of highly active synthetically derived flavon-3-ol derivatives were 
investigated for their positive modulatory effects on IGABA. They were found to preferentially 
bind to α2 containing receptors compared to α1, exerting the expected anxiolytic effects in vivo 
without inducing sedation (Fernandez et al., 2008). Furthermore it was possible to define 
distinct structural features for IGABA enhancement - trans-configuration of the residues in 
positions 2 and 3, acetylation of the hydroxyl group in position 3 and methoxy substituents at 
the B ring (Mewett et al., 2009).  
Moreover, baicalin (Wang et al., 2008), 6-hydroxyflavone (Ren et al., 2010) and 2’-OH-
flavones (Huen et al., 2003) target the GABAA receptor and partly display anxiolytic activity 
in vivo. Additionally, certain flavonoid-glycosides seem to exert effects on the GABAA 
receptor e.g. linarin and hesperidin (Fernández et al., 2004). Controversially, in a study from 
Fernandez et al. (2006), it was found that other flavonoid glycosides, although expressing 
affinity for the BZ binding site, did not positively enhance IGABA in a functional assay in vitro. 
Nonetheless, they showed anxiolytic activity in vivo (Fernández et al., 2006). A compound  
related to the flavonoids - epicatechingallate - also displayed second order modulatory 
activity, comparable to apigenin (Campbell et al., 2004).  
 
Fragrances in food stuff and alcoholic beverages 
A range of aliphatic alcohols and aldehydes have been investigated for their effects on the 
GABAA receptor, whereby most of these components are fragrant/volatile substances found in 
different alcoholic beverages or in food stuff e.g. octen-3-ol, sotolone, cis-jasmone (Fig. 6E, 
p.15), or leaf alcohol (Aoshima and Hamamoto, 1999; Aoshima et al., 2001; Hossain et al., 
2002; Hossain et al., 2003; Aoshima et al., 2005; Mitou et al., 2008). 
Moreover, ethanol itself is a GABAA receptor modulator and could be considered a natural 
product, since it is biosynthesized from glucose. Many effects of ethanol are mediated via the 
GABAA receptor including impairment in motor function and cognition, sedation and 
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anxiolysis (Kumar et al., 2009). Not surprising, alcohol dependence seems (at least partly) 
mediated by the GABAA receptor as well (Enoch, 2008). 
 
Terpenes  
The class of terpenes is one of the largest natural compound classes and displays great 
structural variety since they can be build from two to several C5- (prenyl-) units. This leads to 
the generation of different terpenoid structures i.e. mono-, sesqui-, di-, tri-, and tetraterpenes. 
Although no tetra-terpenoid compounds are known to interact with the GABAA receptor, 
there are various representatives from each of the other groups exerting effects on this 
receptor. 
 
The mostly volatile monoterpenes (C10) are common constituents of essential oils and one 
can assume that these compounds easily penetrate the blood-brain-barrier giving rise to a 
variety of CNS effects. So far, most of the investigated substances in this group are cyclic 
oxygenated derivatives like the positive allosteric modulators borneol (Fig. 7A, p. 18) which 
can be found in high quantities in Valeriana sp. and Salvia sp (Granger et al., 2005), menthol 
and related compounds from Mentha sp. (Hall et al., 2004a; Watt et al., 2008; Corvalán et al., 
2009), thymol from Thymus sp. (Priestley et al., 2003) - a phenolic monoterpene - or linalool, 
which is a compound found in numerous essential oils (Aoshima and Hamamoto, 1999). 
Additionally, the convulsant thujone from Artemisia absinthium L. was found to be a negative 
allosteric modulator of GABAA receptors (Hold et al., 2000). 
The C15 compounds, the sesquiterpenes, do not only exhibit convulsant activity, as it is long 
known for picrotoxinin (Fig. 7B, p. 18) from Anamirta cocculus (L.) Weight & Arn. (Ticku 
and Maksay, 1983) or for bilobalide (Fig. 7D, p. 18) from Gingko biloba L. (Huang et al., 
2003). Valeriana officinalis, used in European phytotherapy as anxiolytic and sedative agent, 
contains next to GABAergic borneol and linarin the positive modulator valerenic acid (Fig. 
7C, p. 18). While valerenic acid even displays certain selectivity for β2-subunit containing 
receptors, the related acetoxy-valerenic acid and hydroxyl-valerenic acid are not able to 
enhance IGABA (Khom et al., 2007). In addition, valerenic acid and some synthetic derivatives 
show promising anxiolytic activity in vivo (Khom et al., 2010). 
In search of insecticidal components, antagonists for the GABAA receptor were isolated from 
Senecio palmensis (Nees) C. Sm. ex Link. These so called silphinenes are sesquiterpene tri-
lactones and strongly resemble picrotoxinin in structure (González-Coloma et al., 2002). They 
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proved to inhibit Cl- influx into cell cultures and thus are assumed to have antagonistic 
activity on the GABAA receptor (Bloomquist, 2003). 
 
A C20 diterpene - miltirone (Fig. 7E) - was isolated from Salvia millitorrhiza, a TCM herbal 
drug used in the treatment of stroke and, more generally, cardiovascular disease. The 
compound itself and several semi-synthetic derivatives were found to interact with the BZ 
binding site using an in vitro 3H diazepam replacement assay (He et al., 1990; Chang et al., 
1991). 
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Figure 7. Terpenes influencing the GABAA receptor. (A) The monoterpene borneol. (B) The sesquiterpenes 
PTX, (C) valerenic acid and (D) bilobalide. The diterpenes (E) miltirone, (F) ginkgolide basic structure and (G) 
eupalmerin acetate. 
 
 
About 15 years later, functional data on the IGABA effects were gained, at least for miltirone, 
but it neither exerted positive nor negative modulatory activity (Mostallino et al., 2004). 
Nonetheless, miltirone was suggested to inhibit the up-regulation of α4 subunit expression and 
thus probably has ameliorating effects on withdrawal symptoms caused by GABAA receptor 
modulators like alcohol.  
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Related compounds from Salvia officinalis, namely carnosic acid, carnosol and galdosol were 
also found to interact with the GABAA receptor in a binding-study in vivo, although working 
on different binding sites (Rutherford et al., 1992; Kavvadias et al., 2003).  Ginkgolides (Fig. 
7F, p. 18), trilactone diterpenes from Gingko biloba L., displayed inhibitory activity on 
recombinant GABAA receptors (Huang et al., 2003). A rather new class of GABAA receptor 
modulators is the cembranoids, macrocyclic diterpenes from mollusks or corals. In a recent 
study one such compound, eupalmerin acetate (Fig. 7G, p. 18), from Eunicea species (corals) 
displayed positive modulatory activity on the GABAA receptor in vitro probably via the 
neurosteroid binding site (Li et al., 2008).  
 
So far, several triterpenes were found to interact with the GABAA receptor: in a study from 
2003 eight different ginsenosides were tested for their modulatory effects on GABAA 
receptors. It was found that ginsenosides are positive allosteric modulators and that 
ginsenoside C had the strongest ability to enhance IGABA (Choi et al., 2003). The common 
triterpene betulin was investigated for its BZ binding site affinity and anticonvulsive activity 
in vivo. Related compounds betulinic acid and lupeol neither inhibited [3H]flunitrazepam 
binding nor blocked bicuculline and picrotoxinin induced seizures (Muceniece et al., 2008). 
Only recently, triterpenoid constituents from Actaea racemosa L. were found to strongly 
enhance IGABA, with acetyl-shengmanole being the most active component (Cicek et al., 
2010). 
 
Neolignans like honokiol (Fig. 8A, p. 20) and magnolol, dihydrohonokiol-B and some related 
components were investigated for their BZ binding affinity (Kuribara et al., 1998; Squires et 
al., 1999). They displayed anxiolytic-like effects in vivo in mice, using the elevated plus maze 
(EPM) and the Vogel Conflict test. They also seem to exert sedative effects in vivo by 
enhancing pentobarbital induced sleeping time   
 
Polyacetylenes like cicutoxin (Fig. 8B, p. 20), virol A and cunaniol, isolated from water 
hemlock, Cicuta virosa, are antagonist (Uwai et al., 2000) while the polyacetylenic 
compounds  MS-1, -2, and -3 isolated from Cussonia zimmermannii display positive 
modulatory activity on the GABAA receptor with certain selectivity on β2-subunit containing 
receptor subtypes (Baur et al., 2005). 
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Various 
Only recently, a new compound class was discovered to enhance IGABA, a dihydroisocoumarin 
isolated from Haloxylon scoparium displayed positive modulatory effects on GABAA 
receptors (Li et al., 2010b). Another isocoumarin derivative isolated from the fungus 
Neosartorya quadricincta was shown to inhibit [(3)H]ethynylbicycloorthobenzoate (EBOB) 
binding, a compound interacting with the PTX binding site (Ozoe et al., 2004). Thus it was 
concluded that this compound could be a new scaffold for insecticidal drugs.  
Caloporoside (Fig. 8C), a fungal metabolite isolated from Caloporous dichrous, was active in 
TBPS binding assay. Even disaccharides like lactose displayed a certain affinity for the 
GABAA receptor in a TBOB binding assay (Rezai et al., 2003). 
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Figure 8. Examples for other GABAA receptor modulators. (A)The neolignan honokiol, (B) the polyacetylenic 
compound cicutoxin and (C) the benzoic acid derivative caloporoside. 
 
In addition, some constituents already displayed promising activity in vivo without 
investigating the molecular mechanism of action.  For example, dl-tetrahydropalmitate was 
found to exert anxiolytic effects in vivo and this effect could be blocked by flumazenil making 
interactions with the BZ binding site of the GABAA receptor likely (Leung et al., 2003). The 
same is valid for e.g. galphimines from Galphimia glauca (Herrera-Ruiz et al., 2006) or 
polygalasaponins and other components from Polygala species (Duarte et al., 2008; Yao et 
al., 2010) etc. A range of different plants and natural compounds has been investigated for 
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their effects on the GABAA receptor but there is still a vast variety of plants traditionally 
applied as sedatives, anticonvulsants (Risa et al., 2004; Moshi et al., 2005; Jäger et al., 2006; 
Awad et al., 2009a; Pedersen et al., 2009) or anxiolytic agents (Bourbonnais-Spear et al., 
2007; Quinlan, 2010) which lack functional data on their GABAergic activity or where not 
tested in this context so far.  
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1.4 Aim of the study  
In the treatment of anxiety and insomnia people not only rely on synthetic drugs like the 
commonly prescribed benzodiazepines (BZs), but they often use herbal remedies since these 
are considered an effective alternative with lower risk of adverse effects. Some of the more 
popular traditional herbal drugs used in Western countries - like valerian (Valeriana 
officinalis) or kava kava (Piper methysticum) - have already been thoroughly investigated 
regarding their sedative/anxiolytic activity and their mechanism of action. Chinese Medicine 
(CM) also knows several anxiolytic and sedative remedies, but studies uncovering the 
molecular mechanisms underlying the proposed anxiolytic or sedative effects of these herbs 
are rare. Such ethnopharmacological studies are of great importance, since CM still plays a 
very important role in the Chinese health system and, furthermore, there is an ever-increasing 
interest in the Western countries for complementary and alternative medicine (CAM).  
Therefore, in this thesis 14 different Chinese Herbal medicines (CHMs) were selected mostly 
due to their use as sedative and/or anxiolytic agents and investigated for their activity on the 
GABAA receptor. This receptor is strongly involved in the regulation of sleep and arousal as 
well as pathological fear responses i.e. anxiety disorders and a viable target for sedative as 
well as anxiolytic drugs now used in clinics.  
Hence, this work serves two aims. For one, these investigations aim to uncover at least part of 
the molecular mechanism of action using recombinant α1β2γ2S GABAA receptors, since they 
are a highly probable target for anxiolytic and sedative drugs. This would also provide 
scientific evidence for the ethnopharmacological use of the selected CHMs. Second, to isolate 
the compounds mainly responsible for the observed enhancement of IGABA in a bioactivity 
guided approach. This will lead to the discovery of new scaffolds for the development of anti-
anxiety and anti-insomnia drugs. 
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2 Material and Methods 
 
2.1 Plant material 
All plant materials were purchased from Plantasia (Oberndorf, Austria). Voucher specimens 
are deposited in the Department of Pharmacognosy, University of Vienna. 
 
Plant name drug pinyin lot No. voucher No. 
Alibizia julibrissin Durazz. 
(Fabaceae) cortex hé huān pí 710805 JS-11-07-AC 
Alibizia julibrissin Durazz. 
(Fabaceae) flos hé huān huā 410700 JS-11-07-AF 
Arisaema erubescence (Wall.) 
Schott.; A. heterophyllum BL.; A. 
amurense Maxim. (Araceae) 
rhizoma tiān nán xīng 440141 JS-11-07-AE 
Arnebia euchroma (Royle) 
Johnst., 
Lithospermum erythrorhizon 
Sieb. et Zucc. (Boraginaceae) 
rhizoma zǐ cǎo 002/7 JS-11-07-AR 
Atractylodes macrocephala 
Koidz. rhizoma bái zhú 610043 JS-11-07-AM 
Cnidium monnieri (L.) Cuss. Ex 
Juss. (Apiaceae) fructus shé chuáng zǐ 690341 JS-11-07-CM 
Dimocarpus (Euphoria) longan 
Lour. (Sapindaceae) arillus long yǎn ròu 530395 JS-11-07-DL 
Forsythia suspensa (Thunb.) Val. 
(Oleaceae) fructus lián qiào 440410 JS-11-07-FS 
Juncus effusus L. (Juncaceae) medulla dēng xīn cǎo 660558 JS-11-07-JE 
Lilium brownii F.E. Brown var. 
viridulum Baker W; L. 
lancifolium Thunb., L. pumilum 
DC. (Liliaceae)  
bulbus bǎi hé 410169 JS-11-07-LB 
Lophaterum gracile Brong. 
(Gramineae) herba dàn zhú yè 340528 JS-11-07-LG 
Nelumbo nucifera Gaertn. 
(Nymphaceaceae) plumula lián zǐ xīn 520350 JS-11-07-NN 
Polygonum multiflorum Thunb. 
(Polygonaceae) caulis yè jiāo téng 410853 JS-11-07-PM 
Tribulus terrestris L. 
(Zygophyllaceae) fructus cì jí lí 410444 JS-11-07-TT 
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 2.2 Chemicals and reagents 
GABA, diazepam, flumazenil and reagents for ND96 buffer solution were purchased from 
Sigma (Vienna, Austria). All solvents used for extraction, chromatography and other 
phytochemical work were from highest purity grade available and purchased from VWR 
(Vienna, Austria). 
 
2.3 Extraction 
2.3.1 Extracts for initial screening  
Extracts for the pre-liminary activity screening were produced as described in chapter 3.2./ 
manuscript chapter 2.3, p. 42. 
 
2.3.2 n-Hexane extract from Atractylodes macrocephala 
200 g of ground drug were exhaustively extracted with n-hexane on the water bath under 
reflux using 4 x 1 L n-hexane. After evaporation under reduce pressure, this yielded around 6 
g of an oily, yellow residue. 
2.3.3 Ethyl acetate (EtOAc) extract from Juncus effusus 
2.2 kg of ground drug material were extracted on the water bath under reflux. This extraction 
was done portion-wise (between 30 and 50 g each) and exhaustively using 3 x 2 L of EtOAc 
for each portion. After evaporation under reduced pressure 13 g of a dark brown residue were 
gained. 
 
2.4 Chromatography 
 
2.4.1 Thin Layer Chromatography (TLC) 
Stationary phase: aluminum plates coated with silica gel KG60 F254 (Merck, Darmstadt, 
Germany) in varying dimensions (length to width: 10x10, 20x10, 20x12), which are given in 
the respective figure text. 
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The detection reagent anisaldehyde sulphuric acid reagent (ASR), which was used for the 
detection of compounds of A. macrocephala and J. effusus, was composed as following: 
MeOH:HAc:H2SO4conc:anisaldehyd in a ratio of 85:10:5:0.5. Briefly, 0.5 mL anisaldehyde 
were mixed with HAc and MeOH, then H2SO4conc was added drop-wise. 
 
2.4.1.1 Atractylodes macrocephala 
Mobile phase 1: n-hexane:EtOAc (95:5) 
Mobile phase 2: n-hexane:EtOAc (80:20) 
Detection: zones were detected in visible light and under UV366 after spraying with ASR after 
heating for 5 to 10 min at 105 °C.  
 
2.4.1.2 Cnidium monnieri 
Mobile phase: n-hexane:EtOAc (90:10). 
Detection: under UV366 without further reagents. 
 
2.4.1.3 Juncus effusus  
Mobile phase: toluene:EtOAc:MeOH:HAc (35:10:1:2.5). 
Detection: zones were detected in visible light and under UV366 after spraying with ASR and 
heating for 5 to 10 min at 105 °C.  
 
2.4.2 Column Chromatography (CC) 
Stationary phase 1: silica gel KG60 (Merck, Darmstadt, Germany) 
Stationary phase 2: Sephadex LH-20 (Sigma, Vienna, Austria). 
 
2.4.2.1 Atractylodes macrocephala 
Stationary phase 1. 
Mobile phase: n-hexane:EtOAc 95:5. 
Column dimensions for isolation of atractylenolide III: 60 x 0.5 cm i.d. (chapter 3.1, p. 32f.). 
Column dimensions for isolation of atractylenolide II: 60 x 0.5 cm i.d. (chapter 3.1, p. 33f.). 
Column dimensions for isolation of atractylenolide I: 90 x 4 cm i.d. (chapter 3.1, p. 35ff.). 
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2.4.2.2 Cnidium monnieri 
Stationary phase 1. 
Mobile phase for fractionation of CM/HPLC/16 (chapter 3.3, p. 60): n-hexane:EtOAc (95:5). 
Column dimensions for isolation of osthole and imperatorin: 60 x 0.5 cm i.d. (chapter 3.3, 
60). 
 
2.4.2.3 Juncus effusus 
Stationary phase 2. 
Mobile phase for fractionation of JE/VLC/6 (chapter 3.5, p. 86): EtOAc. 
Column dimensions for fractionation of JE/VLC/6 (chapter 3.5, p. 86): 65 x 1.5 cm i.d. 
Mobile phase for fractionation of JE/VLC/5 (chapter 3.5, p. 88): EtOAc:MeOH (95:5). 
Column dimensions for fractionation of JE/VLC/5 (chapter 3.5, p. 88): 70 x 1 cm i.d.. 
 
2.4.3 Vacuum Liquid Chromatography (VLC) 
For all VLC columns following stationary phase was used: silica gel KG60 (Merck, 
Darmstadt, Germany). 
2.4.3.1 Atractylodes macrocephala 
Mobile phases for VLC are given in chapter 3.1, Tab. 2, p. 35, 
Column dimensions for VLC of the n-hexane extract: 90 x 4 cm i.d. (chapter 3.1, p. 35). 
 
2.4.3.2 Juncus effusus 
Mobile phases for VLC are given in chapter 3.5, Tab. 3, p. 85. 
Column for VLC: 65 x 3.5 cm i.d. (chapter 3.5, p. 85). 
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2.4.5 High Performance Liquid Chromatography (HPLC) 
 
Instrument 1: consisting of a PE series 200 autosampler, a PE series 200 pump, a PE DAD 
235C diode array detector and a PE nelson 600 series LINK interface. 
 
Instrument 2: consisting of a DGU 20A5 degasser, a LC-20AD pump, a SIL 20ACHT 
autosampler, a SPD-M20A diode array detector, a CTO-20AC column oven and a CBM-20A 
communication bus module. 
 
Instrument 3: consisting of a SIL-10AP autosampler, two LC-8A pumps, a SPD-M20A diode 
array detector, a FRC-10A fraction collector and a CBM-20A interface. 
Column 1: Hypersil BDS-C18, 250 x 4.6 mm, 5 µm from Agilent Technologies. 
Column 2: Hypersil C-18, 250 x 4.6 mm, 5 µm, from Thermo-Scientific Fisher. 
Column 3: Nucleosil 100-7, C-18, 250 x 21, 5 µ from Machery-Nagel, Düren, Germany. 
 
2.4.5.1 Atractylodes macrocephala  
For analysis and fractionation a method according to Wagner and Bauer (1997) was used, 
with a water (solvent A) and MeCN (solvent B) gradient as following: 62 to 70 % B in 10 
min, 70 to 95 % in 2 min and held at 95 % for 8 min, with a flow rate of 1 mL/min for 
analysis and 27.6 mL/min for HPLC-aided fractionation. 
 
2.4.5.2 Cnidium monnieri 
Analysis and fractionation were accomplished with a method according to Cheng et al. (2007) 
with a gradient consisting of water (solvent A) and MeCN (solvent B): 35 % B for 15 min, 
than increase to 80 % B in 5 min, steady concentration of B for 7 min followed by a decrease 
to 35 % B in 3 min. Analysis was ceased with a 5 min purge at 100 %. Flow rate was set at 1 
mL/min for analysis and 27.6 mL/min for HPLC-aided fractionation. 
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2.4.5.3 Juncus effusus 
Analysis and fractionation were conducted with a water (solvent A)//MeOH (solvent B)-
gradient: 60 to 80 %B in 15 min, with a flow rate of 1 mL/min for analysis and 27.6 mL/min 
for HPLC-aided fractionation. Analysis and fractionation were ceased with a 5 min purge 
phase at 100 % B. 
 
2.5 Mass Spectrometry (MS) 
MS was conducted as described in chapter 3.6, p. 100. 
 
2.6 Nuclear Magnetic Resonance Spectroscopy (NMR) 
2.6.1 NMR of atractylenolide II and III 
NMR of atractylenolide II and III was conducted as described in chapter 3.2, p. 43 and spectra 
are shown in annex I (atractylenolide III) and annex II (atractylenolide II). 
 
2.6.1 NMR of atractylenolide I, osthole, imperatorin, effusol and dehydroeffusol 
NMR of the compounds was done as described in chapter 3.2, p. 43 and 3.6, p. 100. For the 
coumarins osthole (spectra see annex IV) and imperatorin (spectra see annex V) the same 
conditions as described for atractylenolide I (spectra see annex III) were used. 
 
2.7 Expression of GABAA Receptors in Xenopus laevis oocytes 
Expression of GABAA Receptors in Xenopus laevis oocytes was done as described in chapter 
3.2, p. 44, 3.4, p. 67f. and 3.6, p. 101. 
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2.8 Two-microelectrode voltage clamp technique and automated fast perfusion system 
The usage of the two-microelectrode voltage clamp technique and automated fast perfusion 
system was accomplished as described in chapter 3.2, p. 44f., 3.4, p. 67f.  and 3.6, p. 101f.. 
 
2.9 Data Analysis and statistics 
Data analysis was conducted as described in chapter 3.2, p. 45, 3.4, p. 67 and 3.6, p. 102. 
 
 
2.10. Molecular modeling 
Binary classification tree and pharmacophore model were created as described in chapter 3.4, 
p. 69f.. 
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3 Results 
 
In this chapter the results will be displayed in form of three different manuscripts. While the 
first manuscript (chapter 3.2) deals with the GABAA receptor activity of 12 CHMs and 
focuses on A. macrocephala, the other two manuscripts describe the structural requirements 
for IGABA enhancement by coumarin derivatives (chapter 3.4) and the activity of J. effusus and 
two of its constituents (chapter 3.6). Further work and more detailed information on the 
phytochemical part of this work will be presented in separate chapters before the respective 
manuscript.  
 
 
3.1 Isolation of the active principles from Atractylodes macrocephala Koidz. 
 
Atractylodes macrocephala Koidz. (Asteraceae), also called largehead atractylodes, is a 
perennial plant growing in North-Eastern China. It is mainly collected in Zheijiang, Hubei and 
Hunnan province, whereby the plants from Yuqiang, Zheijing province are considered the 
best quality drug. The stem reaches heights of 0.4 to 0.6 m (Prajapati et al., 2003), and is 
topped by big, purple inflorescences (Fig. 9). 
 
         
Figure 9. Aerial parts of A. macrocephala, largehead atractylodes (downloaded from 
http://www.botanyvn.com, 14th of March 2011, 12:02 ) 
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The best time to collect the drug is end of October to beginning of winter. The part of the 
plant used as drug is the rhizome, which should be 2 to 3 years old to reach sufficient 
dimensions. The rhizomes are sliced into 2-3 cm thick slices and then either dried under the 
sun or bake/stir-fried with earth or bran.  
 
  
Figure 10. Whole (A) and sliced (B) rhizome of A. macrocephala, downloaded from http://www.tcmedicine.org, 
at the 28th of December 2010, 18:29 
This drug is called bái zhú, white atractylodes. The name stems from the white crystals found 
on the surface of the dried and sliced drug (Fig. 10). The name white atractylodes also serves 
to distinguish this herbal drug from the related drug cāng zhú, which can be translated as 
black atractylodes (referring to the blackish-grey outer bark) and is derived from A. lancea 
(Thunb.) DC or A. chinensis (DC) Koidz.. Compared to the bái zhú, it contains high amounts 
of essential oil, which are freely visible as red dots sprinkling the surface. For this appearance 
the drug was formerly named chi zhú = red Atractylodes.  
Bái zhú contains non-volatile sesquiterpene lactones and volatile sesquiterpene hydrocarbons, 
as well as polyacetylenes, fatty acids and polysaccharides. It is primarily used as a diuretic, 
digestive and spasmolytic agent; can stop spontaneous sweating and calm the fetus (Bensky  
et al., 2006). Typically, 3-6 g of the drug are used, but the dosage can also go up to 20 g per 
decoction (Zhang, 2007).  
So far, pharmacological investigations of this drug concentrated on its anti-inflammatory, 
anticancer or spasmolytic activity. Nonetheless, one of the most commonly used herbal 
remedies for insomnia is Jia-Wey-Shiau-Yau-San, which contains A. macrocephala, among 
other ingredients. It is also widely prescribed against symptoms related to menopause (Chen 
et al., 2009). Still, no investigations concerning its sedative effects were conducted.  
A B
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After the initial extract screening, where the PE extract proofed to be the most active, semi-
preparative HPLC (instrument 3, column 3) was engaged to fractionate the PE extract (3 x 50 
mg in 4 mL MeCN each, injection volume: 3.5 mL). The following peak-based unification 
yielded 18 fractions in total, whereby fractions number 4 and 8 displayed highest activity. In 
some other fractions, e.g. fraction 18, residual activity could be observed (see chapter 3.2, p. 
48, fig. 3A and p. 54, tab. S1).  
First, fraction 4 and 8 were analyzed by TLC using n-hexane:EtOAc (80:20) as mobile phase. 
After spraying with ASR and heating at 105 °C zones could be detected under UV366. Both 
fractions showed one prominent blue fluorescent zone with Rf values of ~ 0.2 and ~ 0.4. After 
TLC screening, both fractions were subjected to HPLC analysis, displaying only one 
prominent peak each at Rt ~ 4.8 min and ~ 7.2 min (Fig. 11) at 215 nm. According to Wagner 
and Bauer (1997) these peaks are due to atractylenolide III and II, respectively. 
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Figure 11. HPLC chromatograms of (A) fraction 4 and (B) fraction 8.  Analysis method according to Wagner 
and Bauer (1997) with MeCN and water as mobile phase (chapter 2. 4.5.1, p. 27) on instrument 1 employing 
column 1. Injection volume was 20 µL and solutions of 1 mg/mL MeCN were used. Detection wavelength: 215 
nm. 
 
The two fractions were separately subjected to column chromatography (CC). Fraction 
AM/HPLC/4 (19 mg) was dissolved in MeOH and mixed with ~ 40 mg of silica gel. This 
mixture was evaporated to dryness under reduced pressure. For the column silica gel was 
A 
B 
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suspended in a sufficient amount of n-hexane:EtOAc (95:5) for 3 hours before it was filled in 
a glass column (60 x 0.5 cm i.d.). The fraction was then applied on top of the column and n-
hexane:EtOAc (95:5) was used as mobile phase with a flow rate of 20 mL/h. 1 mL fractions 
were collected, resulting in a total of 60 fractions. After TLC screening the first 50 mL 
collected could be discarded (as pre-run), while in fractions 39 - 41 and 43 - 47 prominent 
blue fluorescent zones could be detected.  
While fraction AM/HPLC/4/39-41 yielded 0.5 mg of an oily residue and was considered an 
impurity, fraction AM/HPLC/4/43-47 yielded 14 mg of white crystals. This fraction was 
further analyzed by HPLC (Fig. 12) and 1D- and 2D-1H and 13C NMR identified this 
compound as atractylenolide III, one of the major sesquiterpene lactones of A. macrocephala 
(annex I). 
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Figure 12. HPLC analysis of fraction AM/HPLC/4/43-47 on instrument 2, column 1. Injection volume: 5 µL of 
a solution of the fraction in a concentration of 0.5 mg/mL MeCN. Analysis method according to Wagner and 
Bauer (1997, chapter 2. 4.5.1, p. 27). Sample was injected at minute 10, after column equilibration, resulting in a 
final Rt of 4.9 min. of the major peak. Detection wavelength: 215 nm. 
 
The purification of fraction AM/HPLC/8 (10 mg) was done likewise with n-hexane:EtOAc 
(95:5) as mobile phase and silica gel as stationary phase in a glass column of exactly the same 
dimensions. Fractions of 5 mL were collected, whereby the flow rate was set at 10 mL/h. 
Every 5th fraction was screened by TLC to reveal only one blue fluorescent zone in fraction 
AM/HPLC/4/25 (Fig.13, p. 34). 
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Figure 13. TLC screening of the fractionation of AM/HPLC/8 using silica gel plates (KG60 F254, 20x10) 
revealed one blue fluorescent zone under UV366 after spraying with ASR and heating at 105 °C for 5-10 min. 
The application volume of 20 µL was directly taken from the fractionation vials. 
 
 Thus, fractions 23 to 28 were analyzed (Fig.14) and fractions 23-27 could be unified to yield 
5.6 mg (fraction AM/HPLC/8/23-27). This cumulative fraction was again analyzed by HPLC 
(Fig. 15, p. 35) and the structure was elucidated by 1H- and 13C-NMR as atractylenolide II 
(annex II).  
 
                                        
Figure 14. TLC screening of fractions AM/HPLC/8/23 to -/28 using silica gel plates (KG60 F254, 10x10) 
revealed one blue fluorescent zone under UV366 after spraying with ASR and heating at 105 °C for 5-10 min. 
The applied volume (20 µL) was taken directly from the fractionation vials. 
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Figure 15. HPLC chromatogram of the unified fraction AM/HPLC/8/23-28. HPLC instrument 2, column 1. 
Injection volume: 5 µL of a concentration of 0.5 mg/mL MeCN. Analysis method according to Wagner and 
Bauer (1997, chapter 2. 4.5.1, p. 27).  
 
After determination of atractylenolide III and II as active principles in bái zhú, responsible for 
observed IGABA enhancement, a structurally similar compound, atractylenolide I, was isolated. 
For this, a freshly prepared n-hexane extract (chapter 2.3.2, p. 25) was first subjected to 
vacuum liquid chromatography (VLC) on silica gel (90 x 4 cm i.d.) for rough fractionation. 
Used solvents and solvent mixtures (1.5 L each) as well as the yields are given in table 2. 
 
fraction  solvent ratio yield (mg) appearance 
AM/VLC/1 n-hexane    223 clear 
AM/VLC/2 n-hexane:EtOAc 8:2 2063 yellow 
AM/VLC/3 n-hexane:EtOAc 1:1 1385 yellow 
AM/VLC/4 n-hexane:EtOAc 2:8  281 yellow 
AM/VLC/5 EtOAc     86 light yellow 
AM/VLC/6 MeOH (wash out)  1841 dark brown 
total yield   4889  
Table 2. VLC fractionation of an A. macrocephala n-hexane extract. 
 
 
The VLC fractions were analyzed by HPLC to reveal that AM/VLC/2 contains atractylenolide 
I, II and III (Fig. 16, p. 36).  
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Figure 16. HPLC analysis of the VLC fractions (A) AM/VLC/1, (B) AM/VLC/2 and (C) AM/VLC/3 on 
instrument 2, column 1. Injection volume: 10 µL with a concentration of 1 mg/mL MeCN. Analysis method 
according to Wagner and Bauer (1997, chapter 2.5.4.1, p. 27). Detection wavelength: 215 nm. A-I: 
atractylenolide I, A-II: atractylenolide II, A-III: atractylenolide III. 
  
The fraction was crystallized in n-hexane and could be divided in a crystalline 
(AM/VLC/2/CR, 77 mg) and an oily residue (AM/VLC/2/OR, 1.7 g). Subsequently, both 
residues were analyzed by HPLC (Fig. 17, p. 37) using not only 215 nm but also 255 nm as 
detection wavelength for the simultaneous detection of atractylenolide I, II and III. While in 
AM/VLC/2/CR atractylenolide II and III could be detected, AM/VLC/2/OR contained 
comparably higher amounts of atractylenolide I next to atractylenolide II and III.  
A 
B 
C 
A-III 
A-II 
A-I 
A-III 
3 RESULTS 
 
37 
0 10 20 30 min
0
250
mAU
215nm,4nm (1.00)
0 10 20 30 min
0
100
mAU
255nm,4nm (1.00)
 
0 10 20 30 min
0
2500
mAU
215nm,4nm (1.00)
 
0 10 20 30 min
0
100
200
mAU
255nm,4nm (1.00)
 
Figure 17.  HPLC analysis of AM/VLC/2/OR (A and B) and AM/VLC/2/CR (C and D) using instrument 2 and 
column 1 with the analysis method according to Wagner and Bauer (1997, chapter 2.5.4.1, p. 27). Injection 
volume: 10 µL with a concentration of 1 mg/mL MeCN. Detection wavelength was set at 215 nm (A and C) for 
better detection of impurities and at 255 nm (B and D) for simultaneous detection of atractylenolide I (λmax = 276 
nm), which appears at Rt ~ 10.5 min, with atractylenolide II or III (no absorption at 276 nm).  
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Thus, AM/VLC/2/OR was subjected to CC on silica gel (90 x 4 cm i.d.) using n-
hexane:EtOAc (95:5) as eluent. Flow rate was set at 6 mL/h, whereby 3 mL fractions were 
collected. For TLC screening n-hexane:EtOAc (8:2) was used as mobile phase. Fractions 426 
to 461 contained one prominent blue and some weak to prominent orange fluorescent zones 
when spraying with ASR and subsequent detection under UV366. Thus this fraction was 
unified to AM/VLC/2/OR/421-461 (31 mg), an oily residue with white crystals. It was 
assumed, that the blue fluorescent zone was due to atractylenolide I since the related 
atractylenolide II and III also give blue fluorescent zones under UV366 after spraying with 
ASR. Subsequent HPLC analysis confirmed, that the fraction contained atractylenolide I, 
since Rt and UV spectrum of the major peak were in good accordance with the data published 
by Wagner and Bauer (1997). For purification of atractylenolide I, the fraction was dissolved 
in n-hexane:MeOH (3:1); crystals were washed with MeOH to yield 11 mg. HPLC analysis 
(Fig. 18) revealed one major peak with a λmax of 276 nm. This residue was finally identified as 
atractylenolide I by NMR (annex III).  
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Figure 18. HPLC analysis of fraction AM/VLC/2/426-461 (1 mg/mL MeOH) using instrument 2 and column 1 
with the analysis method published by Wagner and Bauer (1997, chapter 2.5.4.1, p. 27). Injection volume was 10 
µL (0.5 mg/mL MeCN). Detection wavelength was set at 190 nm for better detection of impurities. Inlay: 
spectrum of the main peak at Rt 10.48 min. 
For the following pharmacological studies i.e. concentration response curves and BZ-
experiments higher amounts of atractylenolide II and III were needed. Thus they were isolated 
from fraction AM/VLC/2/CR (77 mg). Again silica gel as stationary phase (70 x 1 cm i.d.) 
and n-hexane:EtOAc (95:5) as mobile phase were used, yielding a total of 550 fractions (flow 
rate 6 mL/h, fraction size: 2 mL). Atractylenolide II (16 mg) could be isolated from fractions 
AM/VLC/CR/95-131, while atractylenolide III (31 mg) was gained from unification of 
fractions 381-421, whereby TLC and HPLC chromatograms were similar to already obtained 
data. 
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3.2 GABAA receptor modulators from Chinese Herbal Medicines traditionally applied 
against insomnia and anxiety (manuscript) 
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Abstract 
Ethnopharmacological relevance: Several Chinese Herbal Medicines (CHMs) are used in the 
treatment of insomnia, restlessness, or anxiety. However, mechanisms underlying this effect 
and scientific proof for their traditional use are scarce.  
 
Aim of the Study: In the present study CHMs were screened for their ability to modulate 
GABA-induced chloride currents (IGABA) and isolate the active principles thus providing 
scientific evidence for their use as sedative and/or anxiolytic agents in CM.  
 
Material and methods: Herbal drugs were extracted successively with petroleum ether, ethyl 
acetate, methanol and water and further fractionated according to their bioactivity. The 
obtained extracts, fractions and finally pure compounds were tested for their ability to 
potentiate IGABA using the two-microelectrode voltage clamp technique on recombinant 
α1β2γ2S GABAA receptors expressed in Xenopus laevis oocytes. 
 
Results: From all tested extracts the petroleum ether extract of Atractylodes macrocephala 
Koidz. rhizomes showed the strongest IGABA potentiation and was studied in more detail. 
This led to the isolation of the main components atractylenolide II and III, which seem to be 
responsible for the observed positive modulation of IGABA (166 ± 12 %, n = 3 and 155 ± 12 %, 
n = 3, respectively) in vitro. They were more active than the analogous compound 
atractylenolide I (96 ± 3 %, n = 3) which differs in an additional double binding in position 9 
and 9a. Furthermore it could be shown that this effect is mediated independently of the 
benzodiazepine (BZ) binding site. 
 
Conclusion: A. macrocephala exerts its in vitro activity on recombinant GABAA receptors 
mainly through the two sesquiterpene lactones atractylenolide II and III (Fig. 1). This positive 
allosteric modulation of IGABA can partially be responsible for the traditional 
ethnopharmacological use of this herbal drug as a sedative. 
 
Keywords: Atractylodes macrocephala, GABAA receptors, sesquiterpene lactones, 
atractylenolide, voltage clamp, positive allosteric modulation. 
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1. Introduction 
In Chinese Medicine (CM) several herbal drugs are applied in the treatment of insomnia or 
anxiety disorders, two highly prevalent mental disorders (Somers et al., 2006; Roth, 2007). 
Although such herbal remedies are frequently used and considered effective and well-
tolerated, studies confirming their ethnopharmacological use are often lacking. From the 12 
Chinese Herbal Medicines (CHMs) we selected for our study, only some have been 
investigated for anxiolytic, sedative or other GABAA receptor related effects in vivo or in 
vitro: sedative effects for flavonoids isolated from Albizia julibrissin flowers (Kang et al., 
2000) and anxiolytic effects through Albizia bark extracts have been already published (Kim 
et al., 2004). Furthermore, the alkaloid harmane isolated from Tribulus terrestris is supposed 
to be mildly sedating and affect the locomotor activity in sheep (Bourke et al., 1992).  
Nelumbo nucifera seed embryos contain isoquinoline alkaloids like neferine and related 
constituents, which seem to have anxiolytic and sedative activity in vivo (Sugimoto et al., 
2008). From Dimocarpus longan, adenosine was determined as the active anxiolytic principle 
in a bioactivity guided approach using the Vogel Conflict Test (Okuyama et al., 1999) and 
sedative-hypnotic activity was published for a decoction from the stem of Polygonum 
multiflorum (Yang et al., 1990).  In search for the (other) molecular mechanism underlying 
these traditional sleep-remedies, they were investigated for their ability to modulate the γ-
aminobutyric acid (GABA) type A (GABAA) receptor. GABA is the major inhibitory 
neurotransmitter in the mammalian brain and hence the GABAA receptor represents a viable 
target when searching for anxiolytic or sedative components from natural origin (Johnston et 
al., 2006; Khom et al., 2007, Trauner et al. 2008; Zaugg et al., 2010). The GABAA receptor 
itself is a heteropentameric ligand gated ion channel responsible for fast inhibition of 
neurotransmission (Mody and Pearce, 2004), whereby from many possible receptor subtypes 
the α1β2γ2S receptor is the most abundant (Moehler, 2006; Olsen and Sieghart, 2008; 2009). In 
the present study effects of different CHM extracts, fractions and isolated compounds on 
GABA-induced chloride currents (IGABA) were investigated using the two-microelectrode 
voltage clamp technique and an automated fast perfusion system on Xenopus laevis oocytes 
expressing α1β2γ2S GABAA receptors. Since the petroleum ether extract of bái zhú (rhizomes 
of Atractylodes macrocephala Koidz.) displayed highest activity it was further investigated 
using a bioactivity III (Fig. 1) guided approach. It was found that the sesquiterpene lactones 
atractylenolide II and are the active principles of bái zhú, which potentiated IGABA 
concentration dependently and independent of the benzodiazepine binding site.  
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Fig. 1. Structures of the sesquiterpene lactones atractylenolide III (1), atractylenolide II (2) and atractylenolide I 
(3). While in atractylenolide III and II a hydroxyl or proton is positioned on C8, atractylenolide I bears an 
additional double bound in position 9 and 9a. 
 
2. Materials 
2.1. Chemicals 
For HPLC and crystallization analytical grade solvents were used. For extraction and isolation 
on silica gel columns solvents of highest available purity were used (VWR, Vienna, Austria).  
Diazepam, flumazenil and ND96 reagents were purchased from Sigma (Vienna, Austria). 
 
2.2. Plant Material 
Herbal drugs were purchased from Plantasia (Oberndorf, Austria). Voucher specimens are 
deposited at the Department of Pharmacognosy, University of Vienna. 
 
2.3. Extraction 
The ground drugs were soaked in 500 mL petroleum ether for 10 min, and extracted on the 
water bath under reflux for 30 min. The obtained extracts were filtered and evaporated to 
dryness. The remaining drug material was air-dried overnight and extracted with each 500 mL 
of ethyl acetate (EtOAc), MeOH and distilled water likewise, whereby the water extract was 
lyophilized.  
 
2.4. Fractionation by semi-preparative HPLC 
HPLC activity profiling was carried out with a Shimadzu instrument consisting of two LC-8A 
pumps, a SIL-10AP autosampler, a SPD-M20A diode array detector, a FRC-10A fraction 
collector and a CBM-20A interface. A Nucleosil 100-7, C-18 (250 x 21, 5µm) column from 
Machery-Nagel (Düren, Germany) was employed. For fractionation following HPLC method 
was used (Wagner and Bauer, 1997): after equilibration (15min) at 62 % acetonitrilee (MeCN, 
solvent B) concentration of B was increased to 70 % B in 10 min, increased to 95 % B in 2 
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min and held on 95 % B for 8 min. A 1 min increase to 100 % B and 5 min purge phase with 
100 % B ceased analysis. Flow rate was 27.8 mL/min and monitoring wavelengths were set at 
190, 215 and 255 nm.  
 
2.5. Isolation  
HPLC fraction 4 (19 mg) was purified on silica gel (60 x 0.5 cm i.d) with n-hexane:EtOAc 
(95:5) as mobile phase and aliquots of 5 mL (flow rate: 20mL/h) were collected. Fractionation 
was monitored by TLC (silica gel KG60 F254, Merck, Darmstadt, Germany) using n-
hexane:EtOAc (8:2) as mobile phase and zones were visualized after spraying with 
anisaldehyde sulphuric acid reagent and heating at 105 °C for 5 to 10 min in visible light and 
under UV366. Unification of fractions 4-386 to 4-421 yielded 14 mg of atractylenolide III 
(purity ≥ 99 %). HPLC fraction 8 (~ 7 mg) was purified by column chromatography on silica 
gel (60 x 0.5 cm i.d.) using n-hexane:EtOAc (95:5), collecting aliquots of 5 mL (flow rate: 10 
mL/h). Fractionation was again monitored by TLC to yield 5.6 mg atractylenolide II (purity ≥ 
99 %) from fractions 8-23 to 8-28. Atractylenolide I was isolated from a n-hexane extract of 
A. macrocephala (50 mg drug/mL n-hexane; 6 g extract in total). This extract was first 
subjected to VLC using the following solvents and solvent mixtures: n-hexane, n-
hexane:EtOAc (8:2), n-hexane:EtOAc (1:1), n-hexane:EtOAc (2:8), EtOAc, EtOAc:CHCl3 
(1:1), CHCl3, CHCl3:MeOH (1:1), MeOH, MeOH:water (1:1) and water. The fraction (VLC2) 
gained from n-hexane:EtOAc (8:2) was further purified by column chromatography (90 x 4 
cm i.d.) using n-hexane:EtOAc (95:5) as mobile phase (6 mL/h, 3 mL for each fraction). 
Fractionation was monitored by TLC. Fractions containing atractylenolide I (VLC2-426 to -
461) were unified, crystallized in n-hexane:MeOH (3:1), and washed with MeOH to give 11 
mg of pure compound (purity ≥ 98 %).  
 
2.6. Spectroscopy 
The isolated compounds were identified using NMR. Spectra for atractylenolide II and III 
were recorded on a Bruker Advance DRX 400 NMR with a resonance frequency at 600.13 
MHz for 1H NMR and at 150.92 MHz for 13C NMR. Spectra for atractylenolide I were 
recorded in CD3Cl or d6-DMSO on a Bruker Advance 500 spectrometer at 500 MHz (1H 
NMR) and 125 MHz (13C NMR).  
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2.7. Expression of GABAA Receptors 
Preparation of stage V-VI oocytes from Xenopus laevis (NASCO, Fort Atkinson, WI, USA) 
and injection of cRNA were done as previously described (Khom et al., 2006). 15 min prior to 
surgery female frogs were anaesthetized using a 0.2 % solution of MS-222 (Ethyl 3-
aminobenzoate methanesulfonic acid, Sigma, Vienna, Austria). Parts of the ovaries were 
removed and remaining follicle membranes were enzymatically digested with 2 mg/mL 
collagenase Type 1A (Sigma, Vienna, Austria). Synthesis of capped off run-off poly (A+) 
cRNA transcipts was performed from linearized cDNA templates (pCM vector). cRNAs were 
diluted with DEPC-treated water and stored at -80 °C. Injection of 10 – 50 nL of the different 
cRNA solutions was carried out on the day of isolation. To ensure the expression of the γ-
subunit cRNAs of α1, β2 and γ2S were injected in a ratio of 1:1:10 (Baburin et al., 2008; 
Boileau et al., 2003). Injected oocytes were stored at 18 °C in penicillin and streptomycin 
supplemented ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2 x 6 H2O, 1.8 mM 
CaCl2 and 5 mM HEPES, pH 7.4).  
 
2.8. Two-microelectrode voltage clamp technique and drug application 
GABAA receptor expressing oocytes were screened for GABA-evoked currents 1 to 3 days 
after cRNA injection as previously described (Baburin et al., 2006). Electrophysiological 
experiments were performed by the two-microelectrode voltage clamp technique making use 
of a TURBO TEC-03X amplifier (npi electronic, Tamm, Germany) at a holding potential of -
70 mV. Current measurements were digitized at 200 Hz and recorded with pCLAMP 10 data 
acquisition software (Molecular Devices, Sunnyvale, CA, USA). ND96 was used as bath 
solution. Glass electrodes (Harvard Apparatus, Kent, UK) were made using a micropipette 
puller (Narishige, Tokyo, Japan) and filled with 2 M KCl (1 – 3 MΩ). Oocytes with maximal 
current amplitudes ≥ 3 µA were discarded to exclude voltage clamp errors. 
All experiments were performed at room temperature (23 to 25 °C). Stimulation of chloride 
currents by extracts and pure compounds was determined at a GABA concentration eliciting 
between 1 and 10 % of the maximal current amplitude (EC1-10) and normally equaled a 
concentration between 1 and 10 µM GABA, depending on the oocyte. The GABA 
concentration needed for the measurements was established at the beginning of each 
experiment. Stock solutions of the extracts (10 mg/mL) and compounds (100 mM) were 
prepared in DMSO and stored at -20 °C, except for the 1mM GABA stock solution where ND 
96 was used. Reservoirs for control and drug applications contained equivalent amounts of 
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DMSO, which did not exceed 1 %. At this concentration the measurements were not 
influenced. All stock solutions were dissolved in ND96 containing the appropriate amount of 
GABA to elicit currents of EC1-10 immediately before the experiments, and the extracts were 
always diluted to a concentration of 100 µg/mL. Test solutions (100 μL) were applied to the 
oocytes at a speed of 300 μL/s by means of a ScreeningTool (npi electronics, Tamm, 
Germany) according to Baburin et al. (2006). A 5 to 10 min washout period was allowed 
between drug applications (concentration ≥ 30 µM) to avoid receptor desensitization. 
 
2.9. Data Analysis 
Potentiation of the GABA-induced chloride current (IGABA) in percent was defined according 
to the formula [I(GABA+Comp)/IGABA- 1]*100, where I(GABA+Comp) is the current response in the 
presence of a given compound, and IGABA is the control GABA-induced chloride current. 
Origin Software (OriginLab Corporation, Northhampton, MA, USA) was used to generate 
concentration-response curves. Data were fitted by nonlinear regression analysis to the 
equation 1/(1+(EC50/[compound]nH), where EC50 is the concentration of the compound that 
increases the amplitude of the GABA-evoked current by 50% of the compound-induced 
maximum response, and nH is the Hill coefficient. Responses were graphed as mean ± 
standard error (S.E.M.) from at least three oocytes out of ≥ two different batches. Statistical 
significance (*) was calculated using Student’s t-test and one-way ANOVA with a confidence 
interval of p < 0.05. 
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3. Results 
 
3.1. Screening of herbal extracts and fractions for modulation of IGABA  
In total 48, e.g. 4 extracts of different polarity from 12 TCM herbal drugs (Tab. 1), were 
investigated for their ability to enhance IGABA. From these 48 extracts in total, the lipophilic 
extracts from A. macrocephala showed the most promising enhancement of IGABA (Fig. 2, 
Tab. 1) with the petroleum ether extract displaying the highest activity (322 ± 48 %, n = 3).  
 
 
Fig. 2. Preliminary activity screening of the 48 different extracts (100 µg/mL). Potentiation of IGABA was 
measured at EC1-10. CHM are abbreviated according to Table 1 with the plant name initials. 1 = PE/petroleum 
ether, 2 = ethyl acetate/EtOAc, 3 = MeOH, 4 = water/H2O 
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Abb. Plant name drug pinyin Potentiation of IGABA ± SEM (%) 
    PE EtOAc MeOH water 
AC 1Alibizia julibrissin Durazz. (Fabaceae) cortex 
hé huān 
pí 
18 ± 
4 12 ± 6 7 ± 3 -9 ± 5 
AF 1Alibizia julibrissin Durazz. (Fabaceae) flos 
hé huān 
huā 
11 ± 
11 1 ± 8 0 ± 5 2 ± 6 
AR 1Arisaema erubescence (Wall.) Schott.; A. 
heterophyllum BL.; A. amurense Maxim. 
(Araceae) 
rhizoma 
tiān nán 
xīng 
-3 ± 
9 -2 ± 3 1 ± 3 -25 ± 8 
AE 2Arnebia euchroma (Royle) Johnst., 
Lithospermum erythrorhizon Sieb. et Zucc. 
rhizoma zǐ cǎo 44 ± 
13 21 ± 5 3 ± 3 -8 ± 10 
AM 1Atractylodes macrocephala Koidz. rhizoma bái zhú 322 
± 48 
194 
±78 
76 ± 
10 
22 ± 
14 
DL 3Dimocarpus (Euphoria) longan Lour. 
(Sapindaceae) 
arillus 
long yǎn 
ròu 6 ± 3 -6 ± 1 8 ± 5 13 ± 5 
FS 3Forsythia suspensa (Thunb.) Val. 
(Oleaceae) 
fructus lián qiào 92 ± 
34 11 ± 2 7 ± 8 -19 ± 3 
LB 1Lilium brownii F.E. Brown var. viridulum 
Baker W; L. lancifolium Thunb., L. 
pumilum DC. (Liliaceae)  
bulbus bǎi hé 36 ± 
8 95 ± 25 85 ± 6 4 ± 13 
LG 3Lophaterum gracile Brong. (Gramineae) herba 
dàn zhú 
yè 6 ± 2 6 ± 6 -5 ± 14 -17 ± 6 
NN 4Nelumbo nucifera Gaertn. 
(Nymphaceaceae) 
plumula 
lián zǐ 
xīn 
-9 ± 
5 
-12 ± 
26 -16 ± 8 -10 ± 4 
PM 1Polygonum multiflorum Thunb. 
(Polygonaceae) 
caulis 
yè jiāo 
téng 
33 ± 
16 -2 ± 15 -1 ± 8 -2 ± 7 
TT 5Tribulus terrestris L. (Zygophyllaceae) fructus cì jí lí -44 ± 
14 -5 ± 6 7 ± 8 14 ± 2 
1(Bensky  et al., 2006), in the case of Arisaematis rhizome prep. we refer to its use against convulsions since 
anti-epileptic agents can target the GABAA receptor as well 
2referring to its heat-clearing effects which can possibly be also/ translated with “mind-cooling”, meaning 
sedating or anxiolytic, http://alternativehealing.org/zi_cao.htm 
3(Hempen, 2007) 
4(Sugimoto et al., 2008) 
5(Huang, 1999) 
Tab. 1. Selected 12 TCM herbal drugs for screening on recombinant α1β2γ2S GABAA receptor expressed in X. 
laevis oocytes. Footnotes indicate literature where the respective plant is mentioned as a sedative and/or  
anxiolytic agent. The extract-induced potentiation of IGABA is given as mean ± S.E.M from n = 3, from ≥ two 
different batches, whereby the extracts were always tested in concentrations of 100µg/mL. 
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Consequently, this extract was subjected to fractionation by semi-preparative HPLC fractions 
were first collected in a time-based manner and then combined according to the most 
prominent peaks. This lead to a total of 18 fractions from which HPLC fractions 4 (118 ± 7 
%, n = 4), and 8 (109 ± 3 %, n = 4) showed the strongest IGABA enhancement (Fig. 3, Supp. 
Tab. 1).  
 
A 
 
B 
 
Fig. 3. (A) Fractionation pattern of Atractylodes petroleum ether extract. (B) Modulation of IGABA by the 18 
fractions gained from semi-preparative HPLC. Bars represent mean ± S.E.M from at least three oocytes from ≥ 
two different batches. (*) indicates statistically significant (p < 0.05, Student’s t-test). Fractions were tested in a 
concentration of 100 µg/mL.  
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Fractions 4 and 8 were each purified on silica gel (60 x 0.5 cm i.d.) with n-hexane:EtOAc 
(95:5) as eluent, leading to the isolation of atractylenolide III and II, respectively. Structures 
were confirmed by 1H and 13C-NMR and were in good accordance with published data 
(Hikino et al., 1962). Another major component of A. macrocephala is the sesquiterpene 
lactone atractylenolide I (Fig. 1.3), which only differs from atractylenolide II and 
atractylenolide III by an additional double bound in position 9 and 9a. Interestingly, the 
HPLC fraction (fraction 11) which -according to Wagner and Bauer (1997) - contains 
atractylenolide I did not show promising activity in the screening. Thus atractylenolide I was 
isolated and investigated additionally to the above mentioned analogues, to gain first insights 
in the structure-activity relationship between these three sesquiterpene lactones. Spectral data 
of atractylenolide I was  compared with literature (Endo et al., 1979) and in good accordance 
to the published data. 
 
 
3.2. Concentration-dependent modulation of IGABA by atractylenolides I, II and II 
 
Since the atractylenolides II and III (Fig. 1) were the most active constituents they were 
studied in more detail. For both compounds a concentration dependent potentiation of IGABA 
was observed (Fig. 3).  
 
 
 
Fig. 4. Concentration dependent modulation of IGABA by (▲) atractylenolide III, (?) atractylenolide II and (●) 
atractylenolide I. (A) Concentration response curves of the three sesquiterepene lactones. (B) Typical GABA 
control current (single bar) and currents induced by co-application of GABA and A-II (double bar). Pure 
compounds were applied in concentrations ranging from 1 to 1000 µM. Each data point represents the mean ± 
S.E.M from 3 oocytes and at least two different batches. 
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Atractylenolide II, co-applied in concentrations from 1 to 300 µM with GABA concentrations 
corresponding to EC1-10 gave a maximum potentiation of 166 ± 12 %, with a half-maximum 
potentiation (EC50) by 70 ± 17 µM and a Hill coefficient (nH)  
of  1.2 ± 0.1 (n = 3). The highest enhancement by atractylenolide III was 157 ± 12 % (EC50: 
99 ± 20 µM, nH: 1.5 ± 0.4, n = 3). The related atractylenolide I displayed a lower IGABA 
modulation by 96 ± 3 % (EC50: 12 ± 1 µM, nH: 2.5 ± 0.2, n = 3). 
 
 
3.3. Benzodiazepine binding site independent modulation by atractylenolide II  
 
To determine if the sesquiterpene lactones modulate GABAA receptors by interaction with the 
benzodiazepine (BZ) binding site, atractylenolide II was used as a representative compound 
for this experiment.  
Potentiation of IGABA by atractylenolide II (70 µM) was studied in the presence and absence of 
flumazenil (1 µM) or diazepam (300 nM). 
Atractylenolide II-induced enhancement of IGABA was not inhibited by the co-application of 
flumazenil (107 ± 5 % vs. 104 ± 5 %, n =3, Fig 4A). When atractylenolide II (70 µM) was co-
applied with diazepam, an (additive) increase in modulation of IGABA from 97 ± 4 % (n =3) to 
474 ± 109 % (n = 3) was observed compared to IGABA potentiation by diazepam alone (347 ± 
52 %, n = 3, Fig 4C).  
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Fig. 5. Effects of atractylenolide II (A-II) on IGABA in the presence of flumazenil (FLZ) and diazepam (DZP) in 
oocytes expressing α1β2γ2S GABAA receptors. Bars represent the mean ± S.E.M from at least 3 oocytes, from ≥ 
two different batches. Statistical significance (p < 0.05, one-way ANOVA) is indicated with (*), n.s. = not 
significant (p > 0.05). (A) Potentiation of IGABA (EC5-10) by A-II (70 µM) in the absence (left bar) and presence 
(right bar) of flumazenil (1 µM) is not significantly different (p > 0.05), indicating no involvement of the BZ 
binding site in the positive modulatory activity of A-II. (B) Typical GABA-induced chloride currents in the 
absence (GABA 3 µM, control, single bar) and presence of the indicated concentrations of A-II (double bar), or 
A-II and flumazenil (triple bar), respectively. (C)  Additive effects of A-II and diazepam on IGABA. The left bar 
shows the potentiation of IGABA by 70 µM A-II, the middle bar by 300 nM diazepam, and the right bar illustrates 
the stimulation of IGABA by co-application of A-II and diazepam. (D) Representative chloride currents induced by 
GABA (3 µM, control, single bar), by A-II (double bar), by diazepam (double bar) and A-II co-applied with 
diazepam (triple bar) at the indicated concentrations. 
 
 
 
4. Discussion 
When screening the extracts of 12 different CHMs regarding their ability to potentiate 
GABA-induced chloride currents, extracts from lián qiào (Forsythia suspensa fruits), bǎi hé 
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(Lilium sp. bulbs) and bái zhú (Atractylodes macrocephala rhizomes) displayed highest 
activity. Bái zhú are the sliced dried or fried rhizomes of Atractylodes macrocephala KOIDZ. 
(Asteraceae), which is a perennial herbaceous plant growing in North-Eastern China. This 
herbal drug contains essential oil (mostly sesquiterpene hydrocarbons), furano-sesquiterpenes, 
polyacetylenes and polysaccharides (Bensky et al., 2006; Chen, 1987; Ding et al., 2005; Endo 
et al., 1979). The use of bái zhú is indicated in a variety of disorders, but it is one of the most 
frequently prescribed ingredients in decoctions against insomnia (Chen et al., 2009) and 
traditionally applied in the treatment of anxiety accompanied with heart palpitations (Stahl-
Biskup, 1998). However, to our knowledge this CHM was never investigated for its sedative 
or anxiolytic activities neither in vitro nor in vivo. Nonetheless, some other pharmacological 
effects have been examined according to its traditional use as tonic (Lee et al., 2007), anti-
diabetic (Shan et al., 2003) or anti-abortive agent (Zhang et al., 2000; Zhang et al., 2008). 
Moreover, it displayed neuroprotective (Lin et al., 2009), anti-inflammatory (Dong et al., 
2008; Li et al., 2007) and cytotoxic activities (Huang et al., 2005 ; Wang et al., 2006). From 
all constituents in bái zhú, the sesquiterpene lactones seem to be the active principles 
regarding positive modulatory activity on the GABAA receptor. Among the three compounds 
isolated, atractylenolide II and III showed similar IGABA enhancement, while the analogous 
atractylenolide I had lower efficacy (Fig. 4). This might be due to the additional double bond 
in position 8 and 9, which results in a more rigid structure (Fig. 1). Moreover, it was shown 
that an interaction with the BZ binding site is not likely, since the activity of atractylenolide II 
could not be inhibited by the BZ antagonist flumazenil (Fig. 5). This suggests that BZs typical 
adverse effects are avoided. Interestingly, IGABA enhancement through the petroleum ether 
extract was higher than the effect observed with the isolated compounds. This could be due to 
the loss of highly lipophilic and/or volatile compounds through RP-18 HPLC and following 
evaporation under reduced pressure. But it can also indicate additive and/or synergistic effects 
possibly through compounds that are not active when applied alone. This “second-order-
modulation” of the GABAA receptor was already observed for certain natural compounds 
(Campbell et al. 2004) and would be worth further studies. Although the in vivo 
sedative/anxiolytic activity still needs to be elucidated, a study on the tissue distribution of 
atractylenolide III revealed that it can cross the blood-brain barrier and is enriched in the 
brain, specifically the cerebellum, when given orally to mice (Li et al., 2006). Based on the 
structural similarity this might be true for atractylenolide I and II as well. Thus all three 
components could display positive modulatory activities on the GABAA receptor in vivo 
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resulting in sedation or anxiolysis. This may explain the use of this herbal drug as a traditional 
sedative in CM.  
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Supplementary Tab. 1. IGABA enhancement by the 18 fractions (100 µg/mL) gained from semi-preparative 
HPLC of the A. macrocephala PE extract. Potentiation of IGABA in percent is given as mean ± SEM from 3-4 
oocytes from ≥ two different batches. 
Fraction IGABA potentiation (%) n 
1 -22 ± 2 3 
2 -25 ± 7 3 
3 13 ± 8 3 
4 118 ± 7 4 
5 21 ± 12 3 
6 10 ± 3 3 
7 -7 ±  2 3 
8 109 ± 3 4 
9 -12 ± 6 3 
10 12 ± 8 3 
11 6 ± 4 3 
12 0 ± 0 3 
13 20 ± 7 3 
14 -5 ± 7 3 
15 1 ± 5 3 
16 -13 ± 4 3 
17 0 ± 3 3 
18 53 ± 23 3 
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3.3 Isolation of the active principles of Cnidium monnieri (L.) Cuss. ex Juss. 
Cnidium monnieri (L.) Cuss. ex Juss. (Apiaceae), Monnier's snowparsley, is an annual plant 
growing in many parts of China, but the drug is preferably collected in the East coastal 
provinces of North and North-Eastern China, namely Hebei, Shandong and Zheijiang 
province. The aerial parts reach heights between 0.1 and 0.8 m. The inflorescences form 
umbels, which are 2 to 5 cm in width and each of the finally branching umbellules carry 15 to 
20 diminutive, white flowers (Fig. 19A). The ovoid fruits are very small with 1.5-3 x 1-2 mm 
i.d. (Fig.  19B), (eFloras, 2010).  
 
A    B  
Figure 19. Cnidium monnieri. (A) Cnidium monnieri aerial parts [http://www.horizonherbs.com, accessed 28th 
December, 19:09]. (B) Fruits of Cnidium monnieri photographed by I. Sprinzl (2007). 
 
The ripe fruits are preferably collected in summer or autumn and should be yellowish green in 
color (Zhang, 2007). The drug is either used topically to treat skin diseases like eczema, 
pruritus and scabies or, when applied internally, as an aphrodisiac, analgesic or sedative 
agent. 3-9 g of drug are typically applied for internal use (Zhang, 2007). The main 
constituents in shé chuáng zǐ are fatty acids, essential oil components and coumarin 
derivatives (Bensky et al. 2006). From latter substance class, osthole is one of the major 
compounds found in C. monnieri fruits (Yan et al., 2001) and more thoroughly studied than 
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other constituents. It was investigated for its anti-inflammatory (Liao et al., 2010), cytotoxic 
(Yang et al., 2003; Chou et al., 2007), or even antidiabetic effects (Liang et al., 2009). 
 
From four extracts of different polarity investigated in the preliminary screening, the PE and 
the MeOH extracts displayed similar activity on the GABAA receptor (Fig. 20).  
 
 
Figure 20. Activity screening of the four C. monnieri fruits extracts (100 µg/mL) from different polarity, 
whereby the PE extract displayed slightly higher activity. Bars represent mean potentiation of IGABA ± SEM  in 
percent. Data is derived from at least 3 oocytes from 2 different batches. This data was provided by co-workers 
of the Department of Pharmacology and Toxicology, University of Vienna. 
 
By comparing the HPLC chromatograms of the PE, EtOAc and MeOH extracts, an almost 
identical peak pattern was observed, albeit higher amounts of the main constituents osthole 
and imperatorin can be found in the PE extract (Fig. 21, p. 58). In the water extract no peaks 
could be observed with the HPLC method used and thus it is not depicted in figure 21 (p. 58).  
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Figure 21. HPLC analysis of the different C. monnieri fruit extracts. Instrument 2, column 1 using a 
water/MeCN gradient (Chen et al., 2007a, chapter 2.4.5.2, p. 27). Injection volume was 20 µL and solutions of 1 
mg/mL MeOH were used. (A) Chromatogram of the PE extract. (B) Chromatogram of the EtOAc extract. (C) 
Chromatogram of the MeOH extract. Detection wavelength: 215 nm. 
 
Since the PE extract exerted a slightly higher activity than the MeOH extract it was selected 
for fractionation on semi-preparative HPLC (instrument 3, column 3). For this, a total of 
45mg (dissolved in 4 mL MeCN) of the PE extract were subjected to HPLC for fractionation, 
A 
B 
C 
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whereby only 15 mg extract were used per run to ensure the separation of the two major 
peaks. Fractions were collected volume dependent (13 mL) and unified according to their 
peak pattern to yield 22 fractions in total (Fig. 22). From all fractions, only fraction 
CM/HPLC/16 displayed promising activity (Fig. 23).  
 
 
Figure 22. Fractionation scheme of the PE extract from C. monnieri fruits on instrument 3, employing column3 
using the method from Chen et al (2007a) as described in chapter 2.4.5.2 (p. 27). First the fractions were 
collected volume-dependent, than unified according to their peak pattern. Detection wavelength is set at 280 nm.   
 
 
Figure 23. Activity screening of the HPLC fractions (100 µg/mL) from C. monnieri on α1β2γ2S GABAA 
receptors revealed that fraction 16 showed highest activity (n = 1-2). This data was provided by co-workers of 
the Department of Pharmacology and Toxicology, University of Vienna.  
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Fraction CM/HPLC/16 (~ 15 mg) was therefore subjected to normal phase CC on silica gel 
(60 x 0.5) using n-hexane:EtOAc (95:5) as mobile phase. Fractions of 5 mL were collected 
using a flow rate of 10 mL/h. As shown in figure 24, TLC screening (mobile phase: n-
hexane:EtOAc (90:10), stationary phase: silica gel KG60 F254) revealed to major spots in 
fractions CM/HPLC/16/30-35 (blue fluorescence) and CM/HPLC/16/50-60 (brown 
fluorescence). Consequently, fractions 25 to 36 and fractions 46 to 61 were unified to 
CM/HPLC/16/25-36 (3.1 mg) and CM/HPLC/16/46-61 (5.7 mg). 
 
 
Figure 24. TLC screening of the fractionation of CM/HPLC/16, using silica gel plates (KG60 F254, 20x10). 
Zones could be detected under UV366 without further derivatisation. From every fifth fraction 20 µL, taken 
directly from the fractionation vial, were applied on the plate.  
 
Subsequent HPLC analysis revealed that the unified fractions contained one pure component 
each (Fig. 25, p. 61). Structures were elucidated by NMR to reveal that fraction 
CM/HPLC/16/25-36 contained osthole (annex V) and fraction CM/HPLC/16/46-61 contained 
imperatorin (annex VI).  
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Figure 25. HPLC analysis of CM/HPLC/16/25-36 and CM/HPLC/16/46-61 (each 1 mg/mL MeOH, injection 
volume 10 µL). Instrument 1 and column 1 were employed using an analysis method according to Chen et al. 
(2007a, see chapter 2.4.5.2, p. 27). (A) Chromatogram of the C. monnieri PE extract for comparison (5 mg/mL 
MeOH, 20 µL injection volume). (B) Chromatogram of fraction CM/HPLC/18/25-36. (C) Chromatogram of 
fraction CM/HPLC/16/46-61. 
 
When testing the pure compounds for IGABA potentiation, both displayed positive modulatory 
activity. Interestingly, osthole exerted a 2 times higher enhancement of IGABA than imperatorin 
(125 ± 11 % vs. 54 ± 13 %) when tested in concentrations of 100 µM (Fig. 26, p. 62). This 
suggests, that the activity of coumarin derivatives is dependent on the basic structure i.e. 
higher activity for simply coumarins (osthole) compared to (linear) furanocoumarins 
(imperatorin).  
 
A 
B 
C 
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Figure 26. Potentiation of IGABA by imperatorin and osthole (100 µM) through α1β2γ2S GABAA receptors 
expressed in Xenopus laevis oocytes. Bars represent mean potentiation ± SEM in percent from at least 3 oocytes 
from ≥ 2 different batches. Statistical significance (Student’s t-test, p=0.05) is indicated with (*). 
 
To investigate this hypothesis, other coumarin derivatives – divided in the groups of simple, 
linear furanocoumarins and angular furanocoumarins – were screened for their ability to 
enhance IGABA, to uncover the structural requirements for (positive) IGABA modulation by 
coumarin derivatives.  
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3.4 Insights into structural requirements of GABAA receptor modulating coumarins and 
furanocoumarins (manuscript) 
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This manuscript was submitted to the European Journal of Pharmacology on 21st of 
December 2010. All of the phytochemical work, except NMR measurements and structure 
elucidation (Prof. Ernst Urban, Department of Pharmaceutical Chemistry, University of 
Vienna), as well as the activity screening of the 18 coumarins, concentration-response curves, 
benzodiazepine experiments were done by the author of this thesis. The two components 
osthruthole and ostruthin were isolated by Mag. Sylvia Vogl (Department of 
Pharmacognosy). The pharmacophore model was created partly by the author under 
supervision of Prof. G.F. Ecker (Department of Pharmaceutical Chemistry, University of 
Vienna), whereas the binary classification tree was created by Prof. G.F. Ecker.  
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Abstract  
The coumarins imperatorin and osthole are known to exert anticonvulsant activity. We have 
therefore analyzed the modulation of GABA-induced chloride currents (IGABA) by a selection 
of 18 coumarin derivatives on recombinant α1β2γ2S GABAA receptors expressed in Xenopus 
laevis oocytes by means of the two-microelectrode voltage clamp technique. 
Osthole (EC50 = 14 ± 1 µM) and oxypeucedanin (EC50 = 25 ± 8 µM) displayed the highest 
efficiency with IGABA potentiation of 116 ± 4 % and 547 ± 56 %, respectively. IGABA 
enhancement by osthole and oxypeucedanin was not inhibited by flumazenil (1 µM) 
indicating an interaction with a binding site distinct from the benzodiazepine binding site. In 
general, prenyl residues are essential for the positive modulatory activity, while longer side 
chains or bulkier residues (e.g. geranyl residues) diminish IGABA modulation.  
Generation of a binary classification tree revealed the importance of polarisability, which is 
sufficient to distinguish actives from inactives. A 4-point pharmacophore model based on 
oxypeucedanin - comprising three hydrophobic and one aromatic feature - identified 6 out of 
7 actives as hits.  
In summary, (oxy-)prenylated coumarin derivatives from natural origin represent new 
GABAA receptor modulators. 
 
Keywords: GABAA receptor, (furano)-coumarins, osthole, oxypeucedanin, voltage-clamp 
technique, pharmacophore model 
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1. Introduction 
The gamma-aminobutyric acid type A receptor (GABAA) is a ligand gated ion channel 
mediating fast inhibition of neuronal signal transmission (Mody and Pearce, 2004). Binding 
of GABA to GABAA receptors induces hyperpolarization of the neuronal membrane due to an 
increased chloride influx and thus decreases or inhibits ongoing neurotransmission. The 
GABAA receptors are heteropentameric proteins, which can assembly from 19 different 
subunits: α1–6, β1–3, γ1–3, δ, π, ε, θ, and ρ1-3 and potentially generate a large variety of receptor 
subtypes (Simon et al., 2004). From theoretically over 150.000 possible GABAA receptors 
only a few seem to occur in vivo in the mammalian central nervous system (Olsen and 
Sieghart, 2009). The most abundant receptor subtype consists of 2 α1, 2 β2 and 1 γ2S/L subunit 
(McKernan and Whiting, 1996; Sieghart and Sperk, 2002). While binding of GABA opens 
GABAA receptor channels, there is also evidence for binding sites interacting with 
benzodiazepines, general anesthetics, barbiturates and many other therapeutically important 
drugs (Sieghart, 1995; Korpi et al., 2002; Sieghart and Enna, 2006). In addition to drugs that 
are in clinical use a variety of structurally diverse natural products have been shown to elicit 
positive modulatory effects on GABAA receptors, e.g. borneol (Granger et al., 2005), thymol 
(Priestley et al., 2003), valerenic acid (Khom et al., 2007; Trauner et al., 2008), piperine 
(Zaugg et al.), flavonoids (Huen et al., 2003; Fernandez et al., 2008), polyacetylenes (Baur et 
al., 2005), and various others (Johnston et al., 2006).  
Compared to other natural compound classes like flavonoids or monoterpenes, the action of 
coumarins on GABAA receptors is largely unknown. However, coumarins often occur in 
plants that are used as sedatives or spasmolytic agents in traditional medicinal systems 
worldwide (Murray et al., 1982; O'Kennedy and Thorne, 1997). Furthermore, in vivo 
antiepileptic activity of coumarins was reported by Luszczki and co-workers (Luszczki et al., 
2007a; b; Luszczki et al., 2009a; Luszczki et al., 2009b). 
Evidence for interaction of coumarins with GABAA receptors comes also from binding studies 
suggesting that phellopterin and imperatorin interact with the benzodiazepine binding site of 
the GABAA receptor (Dekermendjian et al., 1996; Bergendorff et al., 1997).  
In the present study we examine the effects of 18 (furano-)coumarins on chloride currents 
(IGABA) through recombinant α1β2γ2S GABAA receptors expressed in Xenopus laevis oocytes 
and provide first insights into the structural requirement for a positive modulatory effect.  
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2. Material and Methods 
 
2.1 Chemicals and substances 
γ-Amino butyric acid (GABA) , reagents for ND96 solution, diazepam and flumazenil were 
purchased from Sigma (Vienna, Austria). Bergamottin, bergapten, bergaptol, coumarin, 
isobergapten, isopimpinellin, scopoletin and umbelliferone were purchased from 
Extrasynthese (Lyon, France). Auraptene and isoimperatorin were purchased from LGC 
Standards (Wesel, Germany). Oxypeucedanin was purchased from Phytolab 
(Vestenbergsreuth, Germany). Phellopterin was purchased from Sequoia Research Products 
Ltd. (Pangbourne, UK). Pimpinellin was purchased from Herboreal Ltd. (Edinburgh, UK). 
Ostruthin (purity ≥ 98 %) and ostruthol (purity ≥ 98 %) were isolated from Peucedanum 
ostruthium L. (Koch) by S. Vogl (Vogl et al., 2011) and imperatorin and osthole were isolated 
from Cnidium monnieri L. as follows: a petroleum ether extract of Cnidium monnieri fruits 
was first subjected to semi-preparative HPLC using a RP-18 column (Nucleosil 100, 
Machery-Nagel) and a gradient elution consisting of H2 (solvent A) and acetonitrilee (solvent 
B) with a concentration of B of 35 % B for 15 min, followed by an increase of B to 80 % in 5 
min and a steady concentration of B for 7 min followed by a decrease to 35 % B in 3 min. 
Flow rate was set at 27.6 mL/min. Fraction 16, which according to literature contains 
imperatorin and osthole, was subjected to normal phase column chromatography on silica gel 
(60 x 0.5 cm i.d.) using n-hexane:EtOAc (95:5) as mobile phase (flow rate 10 mL/h, fraction 
volume: 5 mL). Fractions were screened by TLC on silica gel coated aluminium plates KG60 
F254 (Merck, Germany) using n-hexane:EtOAc (90:10) as mobile phase. Fractions 25-36 
(blue fluorescent zone in the TLC screening) and fractions 46-61 (brown fluorescent spot in 
the TLC screening) were unified to yield two cumulative fractions. Their structure was 
elucidated by 1- and 2-D 1H and 13C-NMR as imperatorin (purity: ≥ 98 %) and osthole 
(purity: ≥ 97 %), respectively. Purity was determined using HPLC by comparing UV spectra 
and retention time to reference substances which were purchased from Sigma (Vienna, 
Austria).  
 
 
2.2 Voltage clamp and fast solution exchange on Xenopus oocytes 
Preparation of stage V-VI oocytes from Xenopus laevis (NASCO, USA) and injection of 
cRNA were done as previously described (Khom et al., 2006). Female frogs were 
anaesthetized 15 min prior to surgery using 0.2 % solution of MS-222 (Sigma, Vienna, 
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Austria) and parts of the ovaries were removed. Remaining follicle membranes were 
enzymatically digested with 2mg/mL collagenase Type 1 A (Sigma, Vienna, Austria). 
Synthesis of capped off run-off poly (A+) cRNA transcripts was performed from linearized 
cDNA templates (pCMV vector). cRNAs were diluted with DEPC-treated water and stored at 
- 80 °C. Injection of 10 - 50 nL of the different cRNA solutions was carried out on the day of 
isolation. To ensure the expression of the γ-subunit, cRNAs of α1, β2, and γ2S were injected in a 
ratio of 1:1:10 (Boileau et al., 2003; Baburin et al., 2008). Successful expression of the γ-
subunit was determined by application of diazepam (300 nM). Injected oocytes were stored at 
18 °C in penicillin and streptomycin supplemented ND96 solution, containing 96 mM NaCl, 2 
mM KCl, 1 mM MgCl2*6H2O, 1.8 mM CaCl2 and 5 mM HEPES (pH 7.4) in double distilled 
water. 
Chloride currents through GABAA receptors were measured by means of the two-
microelectrode voltage clamp method making use of a TURBO TEC 03X amplifier (npi 
electronic, Tamm, Germany) at a holding potential of –70 mV as previously described 
(Baburin et al., 2006). Current measurements were recorded with pCLAMP 10 data 
acquisition software (Molecular Devices, Sunnyvale, CA, USA). ND96 was used as bath 
solution. Microelectrodes (Harvard Apparatus, Kent, UK) with resistances between 1 and 3 
MΩ were pulled by means of a microelectrode puller (Narishige, Tokyo, Japan) and filled 
with 2 M KCl.  
GABA and compounds were applied to oocytes by means of the ScreeningTool (npi 
electronic, Tamm, Germany) fast perfusion system as described by Baburin et al. (2006). 
Stock solutions of the tested compounds (100 mM) were prepared in DMSO and stored at  
-20 °C. GABA and test solutions were prepared freshly every day. The DMSO concentration 
of 1 % in both, the control and test solutions, did not affect GABA-induced chloride current 
(IGABA). In the DMSO-stock solutions (10 mM) and the aqueous test solutions used no 
precipitates or turbidity was observed and thus the compounds were regarded as fully 
dissolved. 
IGABA modulation was measured at a GABA concentration eliciting between 5 and 10 % of the 
maximal current amplitude (EC5-10), corresponding to 3 - 10 µM GABA. The EC5-10 was 
established at the beginning of each experiment. In the presence of compound concentrations 
higher than 30 µM wash out periods were extended to up to 10 minutes to exclude effects of 
receptor desensitization on current amplitudes. 
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2.3 Data analysis 
Compound induced changes in chloride current amplitudes were calculated as 
I(GABA+compound)/IGABA-1, where I(GABA+compound) is the current response in the presence of a 
given compound and IGABA is the control GABA current.  
Concentration-response curves were generated and the data were fitted by nonlinear 
regression analysis using Origin Software (OriginLab Corporation, Northampton, MA, US). 
Data were fitted to the equation 1/(1+(EC50/[compound]nH), where EC50 is the concentration 
of the compound that increases the amplitude of the GABA-evoked current by 50% of the 
compound-induced maximum response, and nH is the Hill coefficient. Responses were 
graphed as mean ± S.E.M. from at least three oocytes out of ≥ 2 different batches. Statistical 
significance (*) was calculated using t-test and one-way ANOVA with a confidence interval 
of P < 0.05. 
 
2.4 Molecular modeling 
Molecules were built using the builder module in MOE 2009.10 and energy minimized using 
standard conditions (MMFF94x force field, adjust H and LP, gradient = 0.01, calculate 
forcefield partial charges). A database was built and a small set of physicochemical 
parameters was calculated. These comprise logP (logP(o/w)), topological polar surface area 
(TPSA), polarisability (apol), molar refractivity (mr), number of rotable bonds (b_1rotN), as 
well as number of H-bond donors and –acceptors. These descriptors allow a general 
description of the physicochemical properties of the molecules and have been successfully 
applied in classification analyses (Demel et al., 2010). The data set was split into two classes, 
active/inactive, with a threshold of 10% potentiation. This resulted in 7 active and 11 inactive 
compounds. Chemical structures, class labels as well as selected physicochemical descriptors 
are given in Table 1. 
 
2.4.1. Binary Classification Tree 
A binary classification tree was built using the QuaSAR-Classify tool in MOE 2009.10 and 
the physicochemical descriptors outlined above. The tree was constructed applying standard 
conditions (number of test samples: 18; number of cross-validation subsets: 2; cross-
validation subset size: 9; random subset selection: on; minimum node size for splitting: 10; 
the maximum growth depth: 10; classes equally important). Quality of the models was 
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assessed by identifying the number of true positives (TP), true negatives (TN), false positives 
(FP) and false negatives (FN) obtained in leave one out cross validation runs. The overall 
prediction accuracy (A), the sensitivity (SE) which represents the accuracy on actives, and the 
specificity (SP), which illustrates the accuracy on inactives, were calculated as follows: A = 
(TP + TN)/(TP+TN+FP+FN), SE = TP/(TP+FN) and SP = TN/(TN + FP).  
 
2.4.2 Creating a pharmacophore model 
3D structures were built interactively using MOE 2009.10. The number of conformers 
generated using the ‘best’ feature of the program for each substrate was limited within the 
program to a maximum of 255 with an energy range of 15.00 kcal/mol beyond the calculated 
potential energy minimum. A 4-point pharmacophore model using the most efficient 
modulator, oxypeucedanin, as template (fig. 7A), was created using the Pharmacophore 
Modeling tools implemented in MOE. The final model features 3 hydrophobic regions at the 
prenyl residue and in position 4 of the carbon skeleton of oxypeucedanin, a position directly 
opposite to the attachment site of the prenyl residue, as well as one aromatic feature. 
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3. Results 
 
3.1. Potentiation of IGABA by osthole and oxypeucedanin 
Recombinant α1β2γ2S receptors were expressed in Xenopus laevis oocytes and GABA-induced 
chloride current (IGABA) modulation by 18 coumarin derivates (Fig. 1, 2) was investigated by 
means of two-microelectrode voltage clamp and a fast perfusion technique (see Methods). 
The 18 tested compounds consist of 6 simple coumarins, 10 linear furanocoumarins and 2 
angular furanocoumarins (Fig. 1).  
 
 
Fig. 1. Structure of the selected compounds divided in the three groups: (A) simple coumarins, (B) linear 
furanocoumarins and (C) angular furanocoumarins (continued on the next page).  
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Fig. 1. continued  
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Fig. 2. Potentiation of IGABA by different coumarins and furanocoumarins (100 µM) from a selection of 18 
coumarin derivatives in oocytes expressing α1β2γ2S GABAA receptors. The compounds are ordered in following 
groups: simple coumarins, linear coumarins and angular coumarins. Within these groups the columns are 
arranged according to the length of the side chain - small (-OH, -OMe), medium (-OC5, -C5) and large (-OC10, -
C10). Statistical significance (t-test, p < 0.05) is indicated with (*). 
 
Oxypeucedanin and osthole at 100 µM enhanced IGABA most efficiently by 550 ± 71 % (n = 5) 
and 124 ± 11 % (n = 5), respectively (Fig. 2, Table 1). The concentration-dependent 
potentiation of IGABA by osthole (maximum enhancement by 116 ± 4 %) is illustrated in Fig. 
3. The EC50 value was determined as 14 ± 1 µM with a Hill coefficient (nH) of 1.4 ± 0.2 (n = 
4).  
The concentration-response curve for oxypeucedanin (EC50 of 26 ± 8 µM, nH = 1.2 ± 0.1, n = 
4) is shown in Fig. 4. Neither of the tested compounds activated the GABAA receptor in the 
absence of GABA in concentrations up to 300 µM suggesting an allosteric modulation. The 
observed enhancement of IGABA was always reversible. 
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Fig. 3. (A) Concentration-response curve for 
IGABA enhancement by osthole (EC50 = 14 ± 1 
µM, nH = 1.4 ± 0.3, n = 4) in oocytes expressing 
α1β2γ2S GABAA receptors. (B) Representative 
currents through α1β2γ2S GABAA receptors in 
the presence of GABA (10 µM, single bar, 
control) and currents and 1, 3, 10, 30, 100 and 
300 µM of osthole (double bar) recorded during 
co-application of GABA (10µM) 
        
Fig. 4. (A) Concentration-response curve for IGABA 
enhancement by oxypeucedanin (OPD, EC50 = 26 ± 8 
µM, nH = 1.2 ± 0.1, n = 4) in oocytes expressing 
α1β2γ2S GABAA receptors. (B) Representative currents 
through α1β2γ2S GABAA receptors in the presence of 
GABA (10 µM, EC5-10, single bar, control) and 
currents recorded during co-application of GABA (10 
µM) and 1, 3, 10, 30, 100 and 300 µM of 
oxypeucedanin (double bar). 
 
 
3.2. Osthole and oxypeucedanin modulate GABAA receptors not via the benzodiazepine 
binding site 
To determine if osthole or oxypeucedanin modulate GABAA receptors by interaction with the 
benzodiazepine binding site, IGABA modulation by these two compounds was studied in the 
presence and absence of flumazenil (1 µM) or diazepam (300 nM). Co-application of 
flumazenil (1 µM) did neither inhibit osthole- (15 µM) nor oxypeucedanin-induced (20 µM) 
potentiation of IGABA (62 ± 6%, n = 4 vs. 68 ± 12 %, n = 4, Fig 5A; and 152 ± 20 %, n = 5 vs. 
153 ± 24 %, n = 5, Fig 6A). When osthole (15 µM) and diazepam (300 nM) were co-applied 
an additive increase in the IGABA amplitude (195 ± 38 %, n = 5) was observed compared to 
IGABA modulation by diazepam (129 ± 19, n = 4) and osthole (60 ± 7 %, n = 5, Fig. 5C).  
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Fig. 5. Effect of osthole (OST) on IGABA in the presence of flumazenil (FLZ) and diazepam (DZP) in oocytes 
expressing α1β2γ2S GABAA receptors. Statistical significance (one-way ANOVA, p < 0.05) is indicated with (*), 
n.s. = not significant (p > 0.05). (A) Stimulation of IGABA by osthole in the presence of flumazenil (1 µM).The 
left bar shows the positive allosteric modulation of the GABA (EC5-10)-induced chloride currents by 15 µM 
osthole. The right bar illustrates that flumazenil (1µM) does not antagonize the osthole-induced enhancement of 
IGABA. (B) Representative currents through α1β2γ2S receptors in the absence and presence of the indicated 
concentrations of osthole or osthole and flumazenil, respectively. The leftmost current represents the GABA 
control current (10 µM, single bar).  (C) Additive effects of osthole and diazepam on IGABA. The left bar 
illustrates the enhancement of IGABA by 15 µM osthole, the middle bar by 300 nM diazepam, and the right bar 
illustrates the enhancement of IGABA by co-application of osthole (15 µM) and diazepam. (300 nM).  (D) 
Representative currents through α1β2γ2S receptors in the absence and presence of the indicated concentrations of 
osthole, diazepam, or osthole and diazepam, respectively. The leftmost current represents the GABA control 
current (10 µM, single bar). 
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Similar observations were made for oxypeucedanin (Fig. 6C, 300 nM diazepam: 130 ± 16 %, 
n = 3, 20 µM oxypeucedanin: 158 ± 26 %, n = 5 vs. oxypeucedanin and diazepam co-applied: 
366 ± 80 %, n = 3).  
 
                 
Fig. 6. Effect of oxypeucedanin (OPD) on IGABA in the presence of flumazenil (FLZ) and diazepam (DZP) in 
oocytes expressing α1β2γ2S GABAA receptors. Statistical significance (one-way ANOVA, p < 0.05) is indicated 
with (*), n.s. = not significant (p > 0.05).  (A) Stimulation of IGABA by oxypeucedanin in the presence of 
flumazenil (FLZ, 1 µM). The left bar shows the positive allosteric modulation of the GABA (EC5-10)-induced 
chloride currents by 20 µM oxypeucedanin. The right bar illustrates that flumazenil (1 µM) does not antagonize 
the oxypeucedanin-induced enhancement of IGABA.   (B) Representative currents through α1β2γ2S receptors in the 
absence and presence of the indicated concentrations of oxypeucedanin, or oxypeucedanin and flumazenil, 
respectively. The leftmost current represents the GABA control current (10 µM, single bar). (C) Additive effects 
of oxypeucedanin and diazepam on IGABA The enhancement of IGABA by oxypeucedanin (20 µM, left bar) or 300 
nM diazepam (middle bar) is increased in an additive manner when oxypeucedanin and diazepam are co-applied 
(right bar).  (D) Representative currents through α1β2γ2S receptors in the absence and presence of the indicated 
concentrations of oxypeucedanin, diazepam, or oxypeucedanin and diazepam, respectively. The leftmost current 
represents the GABA control current (10 µM, single bar). 
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3.3 Isopentenyl residues are a structural requirement for allosteric modulation of 
GABAA receptors 
Insights into the structural requirements for GABAA receptor modulation by coumarins were 
obtained by comparing the action of 18 different coumarin derivatives (Fig. 2, Table 1). From 
the 6 simple coumarins only the prenylated osthole (100 µM) significantly potentiated IGABA 
by 124 ± 12 %. All other coumarins, which contained small hydroxyl or methoxyl groups 
(coumarin, umbelliferone, scopoletin) as well as the components with bulkier 
(geranyl/geranyloxy/other) residues (ostruthin, auraptene), did not enhance IGABA when co-
applied with GABA at 100 µM (Fig. 2, Table 1).  
 
 
Compound Potentiation (%) Class apol a_acc a_don b_1rotN logP(o/w) mr TPSA 
Coumarin 1.5 0 21.44 1 0 0 2.18 4.14 26.30 
Umbelliferone -4.4 0 22.25 2 1 0 1.90 4.26 46.53 
Scopoletin -1.8 0 26.14 3 1 1 1.90 4.90 55.76 
Osthole 124.5 1 39.47 2 0 3 3.20 7.05 35.53 
Auraptene -0.1 0 50.52 2 0 6 3.85 8.85 35.53 
Ostruthin 2.6 0 50.52 2 1 5 3.88 8.81 46.53 
Bergaptol -19.9 0 26.56 2 1 0 2.17 5.16 59.67 
Isopimpinellin 6.3 0 33.56 3 0 2 2.35 6.31 57.90 
Bergapten -10.5 0 29.66 2 0 1 2.43 5.68 48.67 
Isoimperatorin 33.8 1 40.70 2 0 3 3.25 7.49 48.67 
Imperatorin 54.1 1 40.70 2 0 3 3.25 7.49 48.67 
Phellopterin 56.5 1 44.60 3 0 4 3.16 8.13 57.90 
Heraclenin 32.9 1 41.51 3 0 3 2.99 7.45 61.20 
Oxypeucedanin 550 1 41.51 3 0 3 2.99 7.45 61.20 
Bergamottin -7.2 0 54.84 2 0 6 4.11 9.77 48.67 
Ostruthol -6.6 0 57.24 4 1 6 3.06 10.15 95.20 
Isobergapten 4.6 0 29.66 2 0 1 2.43 5.68 48.67 
Pimpinellin 65.4 1 33.56 3 0 2 2.10 6.31 57.90 
 
Table 1. Class labels and selected physicochemical descriptors of the (furano-)coumarins including mean 
potentiation of IGABA by selected coumarin derivatives (100 µM). 7 compounds with an IGABA potentiation above 
20 % were classified as active (1) while the other 11 components were regarded as inactive (0). 
 
 
From the linear furanocoumarins (100 µM), only compounds with oxyprenyl residues 
modulated IGABA. The epoxy-group containing oxypeucedanin (100 µM) induced the strongest 
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potentiation (550 ± 71 %, n = 5, Fig. 2, Table 1). The same concentration of heraclenin 
induced much less IGABA stimulation (33 ± 6 %, n = 3). Other tested furanocoumarins with an 
oxyisopentenyl residue - isoimperatorin, imperatorin, and phellopterin (all at 100 µM) - 
potentiated IGABA by 34 ± 6 % (n = 4), 54 ± 13 % (n = 4) and 57 ± 4 % (n = 3), respectively. 
None of the other components displayed IGABA enhancement above ≥ + 10 %, e.g. the 
furanocoumarins with only methoxy or hydroxyl groups e.g. bergaptol (- 20 ± 5%, n = 4), 
bergapten (- 11 ± 4 %, n = 4) and isopimpinellin (6 ± 5 %, n = 4). The same is valid for the 
furanocoumarins with bulkier residues such as the oxygeranylated bergamottin (- 7 ± 3 %, n = 
4) and the ester compound ostruthol (-7 ± 3 %, n = 3, Fig .2, Table 1). This data correlates 
with the results of the simple coumarin group (see Fig. 1 for classification). Interestingly, 
while the angular furanocoumarin isobergapten showed no activity, its two times 
methoxylated derivative pimpinellin enhanced IGABA by 65 ± 5 % (n = 4). 
 
3.4 Molecular modeling 
First insights into the structural features necessary for significant IGABA potentiation were 
further complemented by preliminary computational studies. As more than half of the 
compounds are inactive, classification algorithms rather than classical QSAR analysis were 
chosen. 
 
 
Fig. 7. Binary decision tree based on polarisability (apol).  
 
Binary classification tree analysis as implemented in the software package MOE revealed a 
highly significant model (total accuracy = 88.9 %) based solely on polarisability (apol) as 
descriptor. Compounds with apol values < 31,6 or > 47,6 are assigned as inactive, whereas 
those exhibiting values within this range show GABA-modulating potency.  
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Furthermore, a pharmacophore model was constructed using oxypeucedanin as template. The 
model consists of three hydrophobic regions and one aromatic feature resulting in 4 false 
positive and 1 false negative annotations.  
 
Fig. 8. 4-point pharmacophore model for coumarins. Superposition of oxypeucedanin with the pharmacophore 
query. Green color indicates hydrophobic regions and orange represents the aromatic feature. 
 
All 4 false positives (ostruthin, auraptene, bergamottin, and ostruthol) are compounds with 
either a geranyl or oxygeranylresidue. To exclude these compounds, several volume exclusion 
domains were placed along the templates, but no decrease in the number of false positives 
was achieved. The inclusion of hydrogen acceptor regions (Acc) in the pharmacophore model 
always led to a reduction of the number of true positives. Further addition of Hyd or AtomQ 
features in the prenyl residue or the ring system had the same effect. The final model (18 
compounds) produced 6 true positives, 7 true negatives, 1 false negative (phellopterin) and 4 
false positives, resulting in an overall accuracy of 72 %, a sensitivity of 86 % and a specificity 
of 64 %. 
 
4. Discussion 
Coumarins are a class of secondary metabolites commonly found in various plant families. 
Despite the well known anticoagulant action of the class of 3-substitued 4-hydroxycoumarins 
(Hirsh et al., 2001; Sadler, 2004; Gebauer, 2007), the pharmacological properties of many 
natural coumarin derivatives are insufficiently characterized (Yarnell and Abascal, 2009). 
Previous studies with (furano)coumarins revealed photosensitizing (Abouelzahab et al., 1987; 
Eisenbrand, 2007), antimicrobial (Widelski et al., 2009; Tsassi et al.), anti-oxidant (Piao et al., 
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2004; Kostova, 2006) and cytotoxic activity (Yang et al., 2003; Thanh et al., 2004; Kostova, 
2005). There is also evidence for neuroprotective (Epifano et al., 2008) and antiepileptic 
effects (Luszczki et al., 2007a; b; Luszczki et al., 2009a; Luszczki et al., 2009b) induced by  
coumarins.  
Effects of coumarins and furanocoumarins on GABAA receptors were first suggested by 
Bergendorff et al. (1997) and Dekermendjian et al. (1996) who observed [3H]diazepam 
displacement in the presence of furanocoumarins, especially phellopterin. Direct evidence for 
potential effects of a furanocoumarin  related substance on the GABAA receptor comes from 
recent studies, which described a positive allosteric modulation of IGABA by a novel plant 
derived dihydroisocoumarin (Li et al., 2010) and coumarins from Angelica pubescens L. 
(Zaugg et al. 2011).  
We have therefore systematically analyzed 18 structurally diverse coumarin derivatives for 
IGABA enhancement. A comparison of their activity on GABAA receptors enabled first insights 
into their structure-activity relationship. From the tested 18 structurally diverse coumarins, 
imperatorin, isoimperatorin, phellopterin, osthole, oxypeucedanin, heraclenin, and pimpinellin 
potentiated IGABA by more than 20 % when applied at 100 µM (Fig. 2). All 7 components, 
except the angular furanocoumarin pimpinellin, bear either an oxyprenyl or a prenyl residue, 
while the position of the side chain varies. This indicates that the C5 side chain represents a 
structural requirement for IGABA modulation. While osthole, the second most active 
compound, is a simple coumarin, the most efficient substance - oxypeucedanin - represents a 
furanocoumarin with an epoxylated oxyprenyl residue. The stabilizing effect of the two 
geminal methyl groups rules out an unspecific effect caused by the chemical reactivity of the 
epoxide moiety. Interestingly, the regioisomeric heraclenin showed a more than 10-fold loss 
of activity (31%). Furthermore, both regioisomers of the respective furanocoumarin analogue 
(isoimperatorin and imperatorin) were almost equally active, which indicates that the different 
activities of oxypeucedanin and heraclenin could be due to the different configuration of the 
chiral center rather than to the different position of the side chain. Extending the prenyl side 
chain of isoimperatorin by one additional isopentenyl moiety (bergamottin) or attaching a 
large and sterically complex group (ostruthol) completely abolished biological activity. 
Finally it’s worth mentioning that in the group of angular furanocoumarins one additional 
methoxy group leads to a remarkable increase in IGABA potentiation (pimpinellin vs 
isobergapten). This also accounts for the configurational isomers pimpinellin and 
isopimpinellin, where the compound with the angular scaffold (pimpinellin) is more active 
than the respective linear analogue (isopimpinellin). 
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In order to gain deeper insights into the molecular features relevant for high biological 
activity, we also performed preliminary computational studies utilizing both a decision tree 
algorithm and pharmacophore modeling.  
A binary classification tree based on a small set of physicochemical descriptors was able to 
classify 17 out of 18 compounds correctly, using only polarisability (apol) as descriptor (Fig. 
7). The only compound miss-classified in this model was isopimpinellin (FP). However, one 
needs to consider that the descriptor used (apol) cannot distinguish between the 
configurational isomeres isopimpinellin (inactive) and pimpinellin (active), giving for both 
compounds a value of 33.56. In conclusion, this model might be useful for predicting the 
activity of structurally analogous derivatives. 
Finally, a pharmacophore model was constructed which could aid in the understanding of the 
main pharmacophoric features necessary for IGABA enhancement by coumarins. Using 
oxypeucedanin as template, 6 out of 7 actives were correctly annotated as active. Having 
additionally 4 false positives, a total accuracy of 72 % with a sensitivity of 86% and a 
specificity of 64% was achieved. The high sensitivity indicates that the model would be a 
versatile tool for in silico screening attempts in order to identify potentially actives out of a 
coumarin-based compound library. The pharmacophore used consisted of three hydrophobic 
regions placed at the prenyl residue and opposite the carbon atom linking the basic skeleton 
with the side chain, and one aromatic feature (Fig. 8). Interestingly, introduction of other 
typical features like hydrogen-bond acceptor zones or an additional aromatic domain could 
not improve the model but rather resulted in assignment of active compounds as false 
negatives. 
However, the feasibility of this 4-point pharmacophore for virtual screening should be taken 
with caution, since these rather unspecific hydrophobic zones will probably lead to a high 
number of false positives when used for screening. Nonetheless, given that geranylated 
coumarins are not active in vitro, screening of a coumarin database which has upfront been 
cleaned from such compounds might lead to interesting new hits, especially when combined 
with the binary classification tree.  
Interestingly, neither osthole nor oxypeucedanin induce a current in the absence of GABA, 
which distinguishes the action of osthole and oxypeucedanin from other modulators like 
etomidate, or the barbiturates. Furthermore, our data clearly show that the two components do 
not interact with the binding sites of the benzodiazepines (Fig. 5 and 6). Future studies 
employing point-mutated receptors will clarify the exact binding site of constituents like 
osthole and oxypeucedanin on the GABAA receptor.  
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The effect of the tested coumarins occurs at very high concentrations which makes a 
therapeutic application unlikely, although all compounds tested met the Lipinski Rule of Five, 
indicating a low risk of insufficient bioavailability. However, it is currently not known if such 
a high concentrations can enter the brain. When referring to their anti-convulsant activity in 
vivo, the high concentrations needed for IGABA by such compounds as imperatorin suggest that 
coumarins exert their effects not exclusively via the GABAA receptor, but may additionally 
interact with other receptors supporting an anticonvulsive (Luszczki et al., 2007a; b; Luszczki 
et al., 2009a; Luszczki et al., 2009b). 
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3.5 Isolation of the active principles from Juncus effusus L. 
Juncus effusus L. (Juncacea), also known as common rush, is a perennial wetland plant 
growing all over the Northern hemisphere. The evergreen plant can reach heights up to 1 m 
and the unobtrusive inflorescences are white with a light-brown calyx (Fig. 27A). In East 
European traditional medicine the rhizomes of J. effusus are used as a diuretic agent for 
dehydration therapies and homeopathic preparations are applied for the treatment of kidney 
stones (Pahlow, 1999). In CM, the inner part of the stem is used to treat insomnia, especially 
in children, and as an antipyretic and diuretic agent. The stem pith – dēng xīn cǎo - is dried 
and then tied into bundles and cut to the same length (Fig. 27B). The drug can also be charred 
before use, but since the dry material is easily inflammable, this is rarely done. This herbal 
drug is normally used in dosages between 1.5 to 4.5 g (Bensky et al., 2006). 
 
   A             B  
Figure 27. (A) Aerial parts of J. effusus downloaded from de.academic.ru on the 20th of December, 2010. (B) 
Typical bundles of J. effusus pith as it is used in CM (photographed by I. Sprinzl, 2007). 
            
Phenanthrenoid compounds seem to represent the major components in Juncus. Additionally, 
some cyclo-artane type triterpenes, flavonoids and phenolic acid derivatives together with 
essential oil compounds, β-sitosterole and α-tocopherol have been already isolated from this 
plant and related species (Bensky et al., 2006). 
After the preliminary extract screening, which revealed high activity for the EtOAc extract, a 
freshly prepared EtOAc extract was produced from approximately 2.2 kg of ground drug. Due 
to its high volume and sponge-like quality, around 200 L EtOAc were needed for the 
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extraction and this was conducted by portion-wise extraction of 30 - 50 g drug/flask, whereby 
each flask could hold a volume of 2 L.  
Finally, 13.4 g of extract could be gained and 10.0 g of this dark brown residue were 
dissolved in EtOAc, mixed with ca. 20 g of silica gel and evaporated to dryness under reduced 
pressure. This mixture was applied on the silica gel column (65 x 3.5 cm i.d.) for VLC. The 
solvent mixtures (1.5 L each) used for VLC and the respective fractionation yields are given 
in table 3. 
 
fraction solvent ratio yield (g) appearance 
JE/VLC/1 PE:EtOAc 9:1 0.33 white 
JE/VLC/2  8.5:1.5 0.47 yellow 
JE/VLC/3  8:2 0.31 orange 
JE/VLC/4  7.5:2.5 0.34 orange-brown with crystals 
JE/VLC/5  6.5:3.5 0.70 brown with white crystals 
JE/VLC/6  6:4 0.96 yellow-brown crystals 
JE/VLC/7  5:5 0.36 dark brown 
JE/VLC/8  3:7 0.53 dark brown 
JE/VLC/9  1.5:8.5 0.39 dark brown 
JE/VLC/10 EtOAc  0.21 dark brown 
JE/VLC/11 MeOH  2.20 dark brown 
TOTAL   6.80  
Table 3. VLC fractionation yields for the J. effusus EtOAc extract.  
 
From the 11 fractions gained, JE/VLC/1 was considered the pre-run fraction and JE/VLC/11 
was the column wash out, thus neither of these two fractions was used for activity screening. 
TLC analysis was conducted with toluene:EtOAc:MeOH:HAc (35:10:1:2.5) as mobile phase. 
Plates were sprayed with ASR and heated at 105 °C for 5-10 min. The zones could then be 
detected under UV366 (Fig. 28, p. 86) and in visible light. This TLC system was used for all 
further analyses. 
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Figure 28. TLC screening of the VLC fractions 1-11 gained from J. effusus EtOAc extract using silica gel KG60 
F254 (20x12) as stationary phase and toluene:EtOAc:MeOH:HAc (35:10:1:2.5) as mobile phase. Application 
volume was 20 µL from solutions of 1mg/mL of each fraction as well as the extract. Extracts were applied for 
comparison on the first and last band. Zones were detected under UV366 after spraying with ASR and heating for 
5-10 min at 105 °C.  
 
Fractions JE/VLC/9 and -/10 were unified according to their similar TLC patterns and the 
unified fraction was used for the activity screening, in which fractions JE/VLC/5 and -/6 
displayed highest activity when tested in concentrations of 100 µg/mL (see Fig. S1, chapter 
3.6, p.105). As can be seen in Fig. 28, these two fractions contain very prominent dark blue-
violet fluorescent zones under UV366, which appear dark violet in visible light. These zones 
could not be detected in the other VLC fractions (JE/VLC/1 to -/4 and JE/VLC/7 to -/10).  
Fraction JE/VLC/6 (0.8 g) was then subjected to CC on Sephadex LH-20 using EtOAc as 
mobile phase. For this, the fraction was dissolved in EtOAc and mixed with 1.6 g of 
Sephadex LH-20, then evaporated to dryness under reduced pressure. This dry, homogenized 
residue was applied on the column (80 x 3 cm i.d.) filled with Sephadex, which was 
previously let to stand for several hours in EtOAc. Fractions of 5 mL each were gained with a 
flow rate set at 10mL/h to yield a total of 320 fractions. Column flow had to be adjusted 
repeatedly during the day to give constant fraction volumes. After TLC screening, the 
fractions were unified according to their TLC pattern to gain 10 fractions in total (Fig. 29, p. 
E              1        2       3         4        5        6         7         8          9       10      11       E   
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87), whereby fraction JE/VLC/6/291-320 was considered the purge phase.  
 
 
Figure 29. TLC screening of the cumulative fractions gained from fractionation of JE/VLC/6 on Sephadex LH-
20 using silica gel plates KG60 F254 (20x10). Application volume for the fractions was 20 µL, which were 
directly taken from the fractionation vials. The left- and the rightmost bands show JE/VLC/6 (1 mg/mL) for 
comparison, whereby 10 µL were applied. -R indicates crystalline residues scraped from the column during this 
specific fractionation times. All bands indicated with -R are crystalline residues of the before mentioned fraction, 
which were scraped from the column outlet to avoid “contamination of the subsequent fractions. Zones were 
detected under UV366 after spraying with ASR and heating for 5-10 min at 105 °C.  
 
 
 
fraction yield (mg)
JE/VLC/6/1-13 51.7  
JE/VLC/6/14-16* 128.7
JE/VLC/6/17-24 41.8
JE/VLC/6/25-30* 7.2
JE/VLC/6/31-34 10.4
JE/VLC/6/35-42* 22.9
JE/VLC/6/43-54* 45.9
JE/VLC/6/55-85* 211.2
JE/VLC/6/86-174 48.4
JE/VLC/6/175-236 9.0
JE/VLC/6/ 291-320 20.4
total 687.4
Table 4. Fractionation yields of JE/VLC/6 on Sephadex LH-20. Fractions used for further activity screening are 
indicated with (*). 
 
VLC/6    1-13       14-16     17-24    25-30     31-34   35-42    43-54   -R      55-85   -R   86-174   -R  175-236   
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For the activity screening only the most distinguishable fractions were used, which are 
marked in table 4 (p. 88) with an asterisk (*). 
When screened for their IGABA potentiation, fraction JE/VLC/6/35-42 displayed highest 
activity (see Fig. S2, chapter 3.6, p. 105). This fraction contained one prominent blue 
fluorescent zone, and two additional, less prominent zones which can be found in other, less 
active fractions as well and thus were not considered the active principle (Fig. 29, p. 87).   
From this active fraction (JE/VLC/6/35-42) only 15 mg were left after the activity screening. 
Hence this compound was enriched from fraction JE/VLC/5, where this blue fluorescent zone 
was also one of the main spots visible on the TLC plate (compare Fig. 28, p. 86). Thus 0.6 g 
of JE/VLC/5 were prepared like JE/VLC/6 and applied on the silica gel column (80 x 3 cm 
i.d.). Instead of EtOAc, EtOAc:MeOH (95:5) was used as solvent and mobile phase. The 
column was set to a flow rate of 10 mL/h and fractions of 5 mL were collected to give 290 
fractions in total.   
 
 
Figure 30. TLC screening of the fractionation of JE/VLC/5 using silica gel plates (KG60 F254, 20x10). Every 
10th fraction from fraction 10 to fraction 130. Application volume for the fractions was 20 µL, which were 
directly taken from the fractionation vial. These fractions were comparable to the VLC fractions JS/421-424, and 
thus not further investigated. The rightmost band shows a 1mg/mL solution of JE/VLC/5 for comparison. E = 
extract. Zones were detected under UV366 after spraying with ASR and heating for 5-10 min at 105 °C.  
 
As can be seen in figure 30, the fractionation of JE/VLC/5 yielded the same compounds that 
are contained in the inactive VLC fractions (compare Fig. 28, p. 86): the red fluorescent zones 
of fraction JE/VLC/1 and 2 are detectable in fractions 10 to 30. The yellow-orange fluorescent 
zones of JE/VLC/3 and 4 can be seen in fractions 40 to 60 and the yellow-brownish 
 10        20        30       40      50        60        70      80        90    100   110    120    130   E   
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fluorescent zones of JE/VLC/4 are visible in fractions 70 - 130.  Starting with fraction 140 
(Fig. 31), the presumably active blue-violet fluorescent zones are detectable, and in fraction 
150 the compound found to be highly active in fraction JE/VLC/6/35-42 seemed to elute as 
pure substance (14 mg). The fractions were unified according to their TLC pattern (Tab. 5). 
 
Figure 31. TLC screening of the fractionation of JE/VLC/5 using silica gel plates (KG60 F254, 20x10). Every 
10th fraction (130 - 220) was applied on the plate (20 µL, taken directly from the fractionation vial). The last four 
bands show residues scrapped from the column outlet (R1-R3) during the fractionation and a 1mg/mL solution 
of JE/VLC/5 for comparison (10 µL). Zones were detected under UV366 after spraying with ASR and heating for 
5-10 min at 105 °C.  
 
fraction yield (mg)
JE/VLC/5/36-47 168.5
JE/VLC/5/61-90 4.4
JE/VLC/5/91-129 10.1
JE/VLC/5/130-140 43.6
JE/VLC/5/141-145 32.9
JE/VLC/5/146-149 21.7
JE/VLC/5/150 13.9
JE/VLC/5/151-156 50.5
JE/VLC/5/157-160 26.3
JE/VLC/5/161-170 55.1
JE/VLC/5/171-230 87.4
JE/VLC/5/231-290 1.1
total 585.6
Table 5. Yields from the fractionation of JE/VLC/5 on Sephadex LH-20. 
 130   140    150    160     170    180     190    200     210    220    R1      R2      R3     VLC/5   
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Fraction JE/VLC/5/150 and the other blue fluorescent zones were compared to JE/VLC/6/35-
42 as well as the initial fractions JE/VLC/5 and -/6 by TLC analysis (Fig. 32) and it was 
observed that both fractions - JE/VLC/5/150 and JE/VLC/6/35-42 - had the same retention 
value. Thus these two fractions were unified to yield 29 mg of a pale brown powder. The 
structure of the compound comprised in this unified fraction was identified by 1- and 2-
dimensional 1H and 13C-NMR as effusol (purity ≥ 96 %, annex VI). 
 
 
Figure 32. TLC screening of the prominent blue fluorescent zones from the fractionation of JE/VLC/5 in 
comparison with JE/VLC/5, -/6 and JE/VLC/6/35-42. Application volume was 20 µL for the fractions and each 
solution was directly taken from the fractionation vials. JE/VLC/5, -/6 and JE/VLC/6/35-42, were dissolved in 
EtOAc (1 mg/mL) and 10 µL were applied on the silica gel plate (KG60 F254, 20x10). Zones were detected under 
UV366 after spraying with ASR and heating for 5-10 min at 105 °C.  
 
 
Following the identification of effusol, another highly prevalent blue fluorescent zone in the 
TLC screening of both – JE/VLC/6 and JE/VLC/5 by TLC – was isolated (see Fig. 29, p. 87: 
JE/VLC/6/55-85; and Fig. 31, p. 89: JE/VLC/5-fractions 170, 180 and 190). This component 
was purified from fraction JE/VLC/6/55-85 by semi-preparative HPLC (instrument 3, column 
3). For this, 30 mg of the fraction were dissolved in MeOH (1.5 mL) and 1.2 mL of this 
solution were injected on the RP-18 column using a gradient consisting of water (solvent A) 
and MeOH (solvent B) with a starting concentration of 40 % B (see chapter 2.4.5.3, p. 28). In 
total 36 fractions (13 mL each) were collected. The fractions 17 to 36 were analyzed by 
analytical HPLC with conditions as described in chapter 2.4.5.3, p. 28), whereby the solutions 
were directly taken from the fractionation vials (Fig. 33, p. 91). 
 
 
 130     135      140    145     150    155     160      165     170    175   VLC6/  VLC5   VLC6 
                       35-42  
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Figure 33. Comparison of JE/VLC/6/55-85 (1 mg/mL) with fractions JE/VLC/6/55-85/21 and JE/VLC/6/55-
85/22 gained from semi-preparative HPLC using instrument 2 and column 2, employing a gradient elution as 
described in chapter 2.4.5.3, p. 28. Injection volume was 10 µL and solutions from fraction 21 and 22 were 
directly taken from the fractionation vial. Detection wavelength: 215 nm. 
 
The main component of fraction JE/VLC/6/55-85 was enriched in fractions JE/HPLC/21 and -
-/22 (Fig. 33). The two fractions were unified to yield 9 mg of a brown residue. The structure 
was identified by NMR as dehydroeffusol (purity ≥ 98 %, annex VII), which differs from 
effusol by an additional double bound in position 9 and 10.  
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Both compounds were tested in further detail regarding concentration-dependent potentiation 
of IGABA and probable interaction with the BZ binding site as described in the next chapter 
(chapter 3.6).  
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The gamma-amino butyric acid (GABA) type A (GABAA) receptor represents a crucial target 
for clinical agents in the treatment of anxiety and insomnia. Using the two-microelectrode 
voltage clamp technique on recombinant α1β2γ2S GABAA receptors, effusol (1) and 
dehydroeffusol (2) were isolated in a bioactivity-guided approach from the pith of Juncus 
effusus L. Both compounds concentration-dependently enhanced GABA-induced chloride 
currents (IGABA) with maximal potentiation of 188±20% (EC50 = 31 ± 8 µM, 1) and 239±18% 
(EC50 = 27 ± 6 µM, 2), independent of the benzodiazepine (BZ) binding site. This activity on 
the GABAA receptor may explain the traditional use of J. effusus as a sedative and anxiolytic 
agent in Chinese Medicine (CM). 
 
 
Anxiety and insomnia are central nervous system disorders with high prevalence, especially in 
developed countries. It is estimated that over 16 % of the world’s population suffer from some 
form of anxiety disorder,1 and more than 30 % frequently experience sleep disturbance.2 
A variety of drugs such as the commonly prescribed benzodiazepines (BZs) are available for 
the treatment of both disorders.3 Although their use is safe compared to the now mostly 
obsolete barbiturates, they can generate a range of adverse effects as lethargy, day-time 
sedation, amnesia or involuntary muscle relaxation. Furthermore, long-term use of BZs, as it 
would be necessary for the treatment of chronic insomnia or anxiety, leads to tolerance 
against the anxiolytic and sedative effects. Moreover, dependence and withdrawal symptoms 
can occur, which further limits their use.4 This high risk of adverse effects combined with the 
limited prescription time of BZs and other conventional drugs5 might be one of the reasons 
why an increasing percentage of insomnia and particularly anxiety patients rely on herbal 
preparations.6 Although the use of herbal drugs is not free of unwanted side effects, they are 
still considered safe, well-tolerated and effective due to the experience gained from long-term 
usage. Nonetheless, scientific evaluation of their activity and underlying molecular 
mechanisms are rare. 7,8  
A Chinese Herbal Medicine (CHM) frequently prescribed against childhood insomnia and 
night terrors, is Junci Medulla – the pith of Juncus effusus L..9 Several compound classes 
were detected in J. effusus: phenanthrene derivatives, cyclo-artane type triterpenes, 
flavonoids, phenolic acid derivatives, as well as essential oil components, β-sitosterol and α-
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tocopherol could already be isolated from J. effusus and related species.10-16 Studies regarding 
their pharmacological activity mainly focus on the phenanthrene derivatives, which displayed 
anti-algal,17 antimicrobial, phototoxic18 and cytotoxic activities.19 Similar compounds derived 
from other plant families were studied for their anticancer, spasmolytic and anticoagulative 
activities.20 Surprisingly, the anti-insomnia and anti-anxiety activities of J. effusus have only 
very recently been investigated in vivo,21 whereas the underlying mechanisms are still 
unknown.  
A key target for sedation and anxiolysis is the γ-amino butyric (GABA) type A (GABAA) 
receptor, which is the major inhibitory neurotransmitter receptor in the mammalian brain. The 
GABAA receptor is a ligand-gated ion channel that transmits its inhibitory signals due to 
opening of a chloride channel and subsequent hyperpolarization of the neuronal membrane. 
The heteropentameric GABAA receptor can be assembled from a range of 19 different 
subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ, and ρ1-3).22 From more than 150.000 possible receptor 
assemblies, only some seem to occur in vivo in the mammalian brain, with the α1β2γ2 receptor 
being the most abundant.23 Interestingly, the GABAA receptor seems to be a valid target for 
natural products, since many plant derived compounds are able to influence the GABAA 
receptor. 29 
In the present study we investigated the effects of J. effusus on recombinant α1β2γ2S GABAA 
receptors expressed in Xenopus laevis oocytes in a bioassay-guided manner. Potentiation of 
GABA-induced chloride currents (IGABA) on the GABAA receptor was determined using the 
two-electrode voltage clamp technique by means of an automated fast perfusion system.  
 
In a preliminary screening of 4 J. effuses extracts of different polarities, the EtOAc extract 
displayed the highest ability to potentiate IGABA (170 ± 24 %, n = 3, Fig. 1) and therefore was 
selected for further bioactivity guided isolation.  
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Figure 1. Potentiation of IGABA by 4 extracts (100 µg/mL) of different polarity (petroleum ether, EtOAc, MeOH 
and water) derived from the pith of Juncus effusus. Bars represent the mean ± S.E.M from at least 4 oocytes, 
from ≥ two different  batches. Statistical significance (p < 0.05, Student’s t-test) is indicated by (*). 
 
 
The EtOAc extract was subjected to vacuum liquid chromatography on silica gel, using 
different mixtures of petroleum ether and EtOAc as mobile phases. The resulting fractions 
were screened for their activity on the GABAA receptor, revealing that only VLC fraction 4 
and 5 could significantly enhance IGABA to almost similar extent (153 ± 48 %, n = 3; and 127 
± 23 %, n = 3; supporting information, Fig. S1). VLC fraction 4 and 5 were sub-fractionated 
by column chromatography on Sephadex LH-20 using EtOAc or EtOAc:MeOH (95:5) as 
mobile phase. Five sub-fractions could be gained from VLC fraction 5 for further activity 
screening, with sub-fraction 5-3 displaying the highest activity (266 ± 58 %, n = 4, supporting 
information, Figure S2). TLC screening revealed one major blue fluorescent zone. The same 
compound was isolated from VLC fraction 4 on Sephadex LH-20 using EtOAc:MeOH (95:5) 
as mobile phase. The compound was identified by MS, 1D and 2D-NMR experiments as 
effusol (1, Fig. 2) and spectral data was in good accordance with the data published in 
literature. 30 Additionally, another predominant constituent was isolated from cumulative 
fraction 5-5, and its structure was determined as dehydroeffusol (2, Fig. 2) by MS and NMR 
experiments and compared to existing spectral data.31  
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Figure 2. Structure of the phenolic phenanthrenes derivatives effusol (1) and dehydroeffusol (2). 
 
To gain further insight into the molecular mechanism of action, both compounds were 
investigated for their ability to potentiate IGABA. 1 and 2 displayed a concentration-dependent 
effect with a maximal potentiation of 188 ± 20 % (EC50 = 31 ± 8 µM, nH = 2.5 ± 0.6, n = 7) 
for 1 and 239 ± 18 % (EC50 = 27 ± 6 µM, nH = 1.4 ± 0.2, n = 4) for 2 (Fig. 3).  
  
 
Figure 3. Concentration-response curve for 1 (▲) and 2 (?), with a maximum potentiation of 188 ± 20 % (EC50 
= 31 ± 8 µM, nH = 2.5 ± 0.6, n = 7) for 1 and 239 ± 18 % (EC50 = 27 ± 6 µM, nH = 1.4 ± 0.2, n = 4) for 2, 
respectively. Each data point represents the mean ± S.E.M from at least 4 oocytes, from ≥ two different batches. 
 
Furthermore, the interaction of 1 and 2 with the benzodiazepine (BZ) binding site was 
determined, since BZs are the most commonly prescribed drugs used in treatment of sleep and 
anxiety disorders. IGABA enhancement induced by 2 (50 µM) could not be blocked by co-
application of the BZ antagonist flumazenil (1 µM, Fig. 4A, B). Moreover, the co-application 
of 2 (50 µM) with diazepam (0.3 µM) leads to an additive increase in IGABA enhancement 
(Fig. 4C, D).  
OH
OH
CH3
OH
CH3
OH
(1) (2)
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Figure 4. Effects of 2 on IGABA in the presence of flumazenil (FLZ) and diazepam (DZP) in oocytes expressing 
α1β2γ2S GABAA receptors. Bars represent the mean ± S.E.M from at least 4 oocytes, from ≥ two different batches. 
Statistical significance (p < 0.05, one-way ANOVA) is indicated with (*), n.s = not significant (p > 0.05). (A) 
Potentiation of IGABA (EC5-10) by 2 (50 µM) in the absence (left bar) and presence (right bar) of flumazenil (1 
µM) is not significantly different (p > 0.05), indicating no involvement of the BZ binding site in the positive 
modulatory activity of 2. (B) Typical GABA-induced chloride currents in the absence (GABA 3 µM, control, 
single bar) and presence of the indicated concentrations of 2 (double bar), or 2 and flumazenil (triple bar), 
respectively. (C)  Additive effects of 2 and diazepam on IGABA. The left bar shows the potentiation of IGABA by 50 
µM 2, the middle bar - by 300 nM diazepam, and the right bar illustrates the stimulation of IGABA by co-
application of 2 and diazepam. (D) Representative chloride currents induced by GABA (10 µM, control, single 
bar), by 2 (double bar), by diazepam (double bar) and 2 co-applied with diazepam (triple bar) at the indicated 
concentrations. 
 
 
Similar results were obtained for 1 (Fig. S3), indicating that both components do not mediate 
their IGABA potentiating effects via the BZ binding site. To summarize, we found scientific 
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evidence for the traditional use of J. effusus on the molecular level and, moreover, the ability 
of 1 and 2 to modulate IGABA may explain its sedative and anxiolytic effects in vivo. 
 
Experimental Section 
General experimental procedures. NMR spectra were recorded in CD3Cl or d6-DMSO on a 
Bruker Advance 500 spectrometer at 500 MHz (1H NMR) and 125 MHz (13C NMR). ESIMSn 
spectra were obtained on a 3D-ion trap mass spectrometer (HCT, Bruker Daltonics) and 
recorded in positive and negative ion mode. Semi-preparative HPLC of compound 2 was 
performed using a Shimadzu system consisting of two LC-8A pumps, a SPD-M20A diode 
array detector, a FRC-10A fraction collector and a CBM-20A interface, engaging a Nucleosil 
C-100 RP-18 column (250 x 21 mm i.d., 5 µm; Machery Nagel, Germany). TLC was carried 
out on precoated silica gel plates KG60 F254 (Merck, Darmstadt, Germany) with 
toluene:EtOAc:MeOH:acetic acid in a ratio of 35:10:1:2.5 as mobile phase. Zones were 
detected in visible light and under UV366 after spraying with anisaldehyde sulphuric acid 
reagent and heating for 5 to 10 min at 105 °C. 
Biological material. Junci medulla, the pith of J. effusus L., was purchased from Plantasia 
(Oberndorf, Austria, lot.: 660558). A voucher specimen (No. JS-07-11-JE) is deposited in the 
Department of Pharmacognosy, University of Vienna.   
Extraction and isolation. For a preliminary activity screening, 50 g of ground plant material 
were extracted successively with solvents of increasing polarity (petroleum ether, EtOAc, 
methanol and water), with the EtOAc extract showing highest activity. Thus, 2.0 kg of ground 
drug were extracted exhaustively with EtOAc to yield 13.4 g of a dark brown residue. 10 g of 
this residue were subjected to vacuum liquid chromatography on silica gel (65 x 3.5 cm i.d.) 
using petroleum ether:EtOAc mixtures (1 L each) in ratios of 9:1 (pre-run), 8.5:1.5, 
8:2,7.5:2.5, 6.5:3.5, 6:4, 5:5, 3:7, 1.5:8.5, 0:10,  from which the latter 9 were used for activity 
testing. Fraction 5 (petroleum ether:EtOAc 6.5:3.5) was further fractionated on a Sephadex 
LH-20 column (65 x 1.5 cm i.d.) using EtOAc as eluent (5mL fractions, 10 mL/h flow) 
resulting in six sub-fractions. Subfraction 5-3 displayed one prominent blue fluorescent zone 
in the TLC screening, which was identified as 1 by MS and NMR experiments and data 
comparison with literature. The crystalline residue of cumulative fraction 5-5, which was 
gained from re-crystallization in EtOAc, was purified by semi-preparative HPLC on RP-18. 
Using a water (solvent A) - methanol (solvent B) gradient from 60 to 80 % B in 15 minutes 
with a flow rate of 26.7 mL/min, compound 2 (9 mg, purity ≥ 98 %) eluted at 9.9 min. VLC 
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fraction 4 (petroleum ether:EtOAc 6:4), which also contained 1 and 2, was fractionated on 
Sephadex LH-20 (70 x 1 cm i.d.) using EtOAc:MeOH (95:5) as eluent to yield 220 fractions 
(5mL fractions, ~ 10 mL/h flow). 1 was eluted as pure compound in subfraction 4-150 (14 
mg, purity ≥ 96 %).  
Expression of GABAA Receptors. Preparation of stage V-VI oocytes from Xenopus laevis 
(NASCO, Fort Atkinson, WI, USA) and injection of cRNA was done as previously 
described.34 Briefly, 15 min prior to surgery, female frogs were anaesthetized using a 0.2 % 
solution of MS-222 (Ethyl 3-aminobenzoate methanesulfonic acid, Sigma, Vienna, Austria). 
Parts of the ovaries were removed and remaining follicle membranes were enzymatically 
digested with 2 mg/mL collagenase Type 1A (Sigma, Vienna, Austria). Synthesis of capped 
off run-off poly (A+) cRNA transcipts was performed from linearized cDNA templates (pCM 
vector). cRNAs were diluted with DEPC-treated water and stored at -80 °C. Injection of 10 – 
50 nL of the different cRNA solutions was carried out on the day of isolation. To ensure the 
expression of the γ-subunit, cRNAs of α1, β2 and γ2S were injected in a ratio of 1:1:10. 
Successful expression of the γ-subunit was determined by measuring IGABA after application 
of diazepam (300 nM). Injected oocytes were stored at 18 °C in penicillin and streptomycin 
supplemented ND96 solution. ND96 solution contained 96 mM NaCl, 2 mM KCl, 1 mM 
MgCl2, 1.8 mM CaCl2 and 5 mM HEPES (pH 7.4). All chemicals for ND96 solution were 
purchased from Sigma, Vienna, Austria).  
Two-microelectrode voltage clamp technique and drug application. 1 to 3 days after 
cRNA injection, GABAA receptor expressing oocytes were screened for GABA-evoked 
currents as previously described.35 Electrophysiological experiments were performed by the 
two-electrode voltage clamp technique making use of the TEC 03X amplifier (npi electronic, 
Tamm, Germany) at a holding potential of -70 mV. Current measurements were digitized at 
200 Hz and recorded with pCLAMP 10 data acquisition software (Molecular Devices, 
Sunnyvale, CA, USA). ND 96 buffer was used as bath solution. Glass needles (Harvard 
Apparatus, Kent, UK) were filled with 2 M KCl (1 – 3 MΩ). Oocytes with maximal current 
amplitudes ≥ 3 µA were discarded to exclude voltage clamp errors. All experiments were 
performed at room temperature (23 to 25 °C). Stimulation of chloride currents by extracts, 
fractions and pure compounds was determined at a GABA concentration eliciting between 5 
and 10 % of the maximal current amplitude (EC5-10). The EC5-10 was established at the 
beginning of each experiment, corresponding to a concentration between 3 and 10 µM 
GABA. Stock solutions of extracts and fractions (10 mg/mL) as well as compounds (100 
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mM) were prepared in DMSO and stored at -20 °C. Reservoirs for control and drug 
applications contained equivalent amounts of DMSO which did not exceed 1 %. At this 
concentration, the measurements were not influenced. All stock solutions were diluted with 
ND96 containing the appropriate amount of GABA to elicit currents of EC5-10 immediately 
before the experiments, whereby the extracts were always diluted to a concentration of 100 
µg/mL. Test solutions (100 μL) were applied to the oocytes at a speed of 300 μL/s by means 
of a ScreeningTool (npi electronic GmbH, Tamm, Germany).3 When compound 
concentrations higher than 30 µM were used, wash out periods were extended to up to 10 min 
to avoid effects of receptor desensitization on current amplitudes.  
Data Analysis. Potentiation of the GABA induced chloride current (IGABA) in percent was 
defined according to the formula [I(GABA+Comp)/IGABA- 1]*100, where I(GABA+Comp) is the current 
response in the presence of a given compound, and IGABA is the control GABA-induced 
chloride current. Origin Software (OriginLab Corporation, Northhampton, MA, USA) was 
used to generate concentration-response curves. Data were fitted by nonlinear regression 
analysis to the equation 1/(1+(EC50/[compound]nH), where EC50 is the concentration of the 
compound that increases the amplitude of the GABA-evoked current by 50% of the 
compound-induced maximum response, and nH is the Hill coefficient. Responses were 
graphed as mean ± standard error (S.E.M.) from at least three oocytes out of ≥ two different 
batches. Statistical significance (*) was calculated using Student’s t-test and one-way 
ANOVA with a confidence interval of p < 0.05. 
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Figure S1. Enhancement of IGABA in oocytes expressing α1β2γ2S GABAA receptors by 9 VLC fractions (100 
µg/mL) derived from the EtOAc extract of Juncus effusus L. Bars represent the mean ± S.E.M from 3 oocytes, 
from ≥ two different batches. Statistical significance (p < 0.05, Student’s t-test) is indicated with (*). 
 
 
 
Figure S2. Potentiation of IGABA in oocytes expressing α1β2γ2S GABAA receptors by the cumulative fractions 
(100 µg/mL) derived from VLC fraction 5. Bars represent the mean ± S.E.M from at least 3 oocytes, from ≥ two 
different batches. Statistical significance (p < 0.05, Student’s t-test) is indicated with (*). 
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Figure S3. Effects of 1 on IGABA in the presence of flumazenil (FLZ) and  diazepam (DZP) in oocytes expressing 
α1β2γ2S GABAA receptors. Bars represent the mean ± S.E.M from at least 4 oocytes, from ≥ two different batches. 
Statistical significance (p < 0.05, one-way ANOVA) is indicated with (*), n.s = not significant (p > 0.05). (A) 
Potentiation of IGABA (EC5-10) by 1 (50 µM) in the absence (left bar) and presence (right bar) of flumazenil (1 
µM) is not significantly different (p > 0.05), indicating no involvement of the BZ binding site in the positive 
modulatory activity of 1. (B) Typical GABA-induced chloride currents in the absence (GABA 3 µM, control, 
single bar) and presence of the indicated concentrations of 1 (double bar),  or 1 and flumazenil (triple bar), 
respectively.  (C)  Additive effects of 2 and diazepam on IGABA. The left bar shows the potentiation of IGABA by 
50 µM 2, the middle bar - by 300 nM diazepam, and the right bar illustrates the stimulation of IGABA by co-
application of 1 and diazepam. (D) Representative chloride currents induced by GABA (10 µM, control, single 
bar), by 1 (double bar), by diazepam (double bar) and 1 co-applied with diazepam (triple bar) at the indicated 
concentrations.  
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4 Discussion 
 
In this work, 14 different CHMs traditionally applied in the treatment of GABAA receptor-
related disease like insomnia or anxiety were investigated for their ability to positively 
modulate IGABA resulting in the discovery of several new positive GABAA receptor 
modulators from natural origin. 
After a vast literature research, 14 herbal drugs were selected which due, to their field of 
application, were expected to exert activity on the GABAA receptor. Next to herbal drugs 
mentioned for the usage against insomnia and anxiety, Arnebia euchroma was solely selected 
for its heat clearing effect while Arisaema sp. was chosen for its use in the treatment of 
“epilepsy”. None of the selected herbal drugs have been studied for their effects on the 
GABAA receptor so far. Nonetheless, some data on the in vivo activity of certain CHMs have 
already been published for Albizia julibrissin, Nelumbo nucifera, Polygonum multiflorum and 
Tribulus terrestris (see chapter 3.2, p 43), and - very recently - Juncus effusus (see chapter 
3.6, p. 94).  
As determined in this thesis, 5 out of 14 herbal drugs displayed promising activity (at least 50 
% potentiation of IGABA), equaling a hit rate of more than 36 %, compared to an average hit 
rate in random screenings of 10 % or below (Harvey, 2002). Of course, when using drugs 
with an ethnomedicinal background time-consuming literature research is necessary to gain 
basic knowledge on the differences in the descriptions of disease patterns in the alternative 
medicinal system compared to conventional medicine and to avoid a replication of already 
published data. CM, for example, insomnia or anxiety can be described as a Yin-Yang 
imbalance, as Heart Blood deficiency, disruptions in the Heart Yin (Kaptchuk, 2000) or, more 
generally, as excess and deficiencies of the zang organs (Kidney, Liver, Heart, Lung or 
Spleen) since they are strongly connected to different emotions (Xinrong, 2003), whereby the 
terms for these organs used in CM does not necessarily correlate with the ones used in 
western medicine. Luckily, due to the ever-increasing popularity of CM, attempts are made to 
translate such symptom patterns into disorders and symptoms observed in conventional 
medicine. Moreover, we already have access to Chinese Materia Medicas in Western 
languages. As can be seen in the Chinese Materia Medica compiled by Bensky et al. (2006) or 
by Zhang et al. (2007), there is a whole chapter regarding tranquillizing herbs. From this 
drug-group Polygonum multiflorum (stem) and Albizia julibrissin (bark and flowers) were 
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chosen for the bioactivity screening on GABAA receptors, while the other drugs contained in 
this chapter were already tested, currently under investigation or of mineralic origin. None of 
these three herbs displayed promising activity in the initial screening while herbal drugs not 
mainly used as “tranquillizers” were more effective on the GABAA receptor.  Thus it is 
apparently worth the effort to study the literature more vigorously, than just selecting the most 
obvious herbal drugs when dealing with as complex a medicinal system as CM.  
In the beginning, 4 extracts of varying polarity (PE, EtOAc, MeOH, water) were produced 
from each of the 14 CHMs, giving a total of 56 extracts. Interestingly, all of the active 
extracts were rather lipophilic while none of the water derived extracts showed promising 
activity. This is promising, since drug like molecules should be rather lipophilic for better 
absorption and distribution in the human body.  In vivo activity of CNS-drugs would require 
the components to penetrate the blood-brain barrier (BBB). From the active sesquiterpene 
lactone atractylenolide III it is already known that it can cross the BBB, since it can be found 
in the brain after oral administration to mice. Due to their high lipophilicity this can also be 
assumed for the prenylated coumarins or the phenanthrenes, but no specific studies on these 
compounds have been conducted so far. Nonetheless, for several coumarins like imperatorin, 
osthole as well as for the phenanthrene dehydroeffsuol a penetration of the BBB is likely, 
since they displayed anti-convulsive or anxiolytic activity in vivo (Luszczki et al., 2007a; 
Luszczki et al., 2009a; Liao et al., 2011) Moreover, compared to hydrophobic, in hydrophilic 
extracts the occurrence of GABA is likely and could give false positive results. These extracts 
would have to undergo an additional separation step to remove GABA from the extract e.g. by 
using ion-exchange chromatography (Trauner et al., 2008). 
After the selection and preliminary activity screening, the most active extracts were further 
fractionated according to their bioactivity. This was accomplished by either using semi-
preparative HPLC, as is the case for A. macrocephala and C. monnieri PE extracts, or 
“classical” fractionation by column chromatography as it is was conducted with the EtOAc 
extract of J. effusus. The advantage of a HPLC-aided fractionation clearly lies in the fastness 
in which first results can be gained. However, since the amount of extract which can be 
separated on a (semi-)preparative HPLC column is limited, repetitive fractionations are often 
necessary to yield amounts high enough for activity testing and further isolation. This was 
true for the PE extracts of A. macrocephala and C. monnieri. Furthermore, both HPLC 
methods used MeCN as organic solvent. Although one can attempt to exchange MeCN with 
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MeOH, latter solvent often does not reach as good a separation and thus the fractionation has 
to be conducted with MeCN. Regrettably, this solvent is rather expensive and, in addition, 
carcinogenic as well as environmentally toxic. Moreover, for fractionation by HPLC a 
suitable method is required and if no method is available the development of one can be as 
time-consuming as normal column chromatography. Although in a first approach, semi-
preparative HPLC was used for the fractionation of the Juncus EtOAc extract as well, the 
yields gained were not high enough for activity testing. Furthermore, the main components 
seemed to appear as one major peak, since in the subsequent TLC analysis several zones were 
visible. Although the gradient was changed repeatedly, they could not be separated. Hence a 
classical column chromatography seemed to be the better choice. For this the EtOAc extract 
was first roughly fractionated by VLC. This method can be conducted rather fast and when 
the solvent or solvent mixtures are chosen cautiously, can yield a good separation as well. 
Moreover, higher quantities of extract can be applied to the column compared to HPLC and 
thus large enough amounts of fractions for subsequent isolation of the active components will 
be received. This makes repetitive fractionation unnecessary compared to semi-preparative 
HPLC. In the end, both methods led to the discovery of new positive GABAA receptor 
modulators and are thus equally suitable for bioactivity-guided isolation.  
By comparing the activity of the isolated compounds with the IGABA enhancement induced by 
the extracts, the latter always showed equal or even higher activity although one would expect 
the fractions to exert significantly stronger IGABA enhancement. For example, the PE extract of 
A. macrocephala potentiated IGABA by ~ 320 %, while the isolated compounds only enhance 
IGABA by a maximum of around 150 %. The same is valid for C. monnieri. Even more so, 
since in the initial screening, the extract showed very promising activity (~ 250 % potentiation 
of IGABA), while the compounds osthole and imperatorin at concentrations of 100 µM 
displayed activities of ~ 120 % and ~ 30 %, respectively. Considering the activity of the 
Juncus EtOAc extract, the results are not as disturbingly different. However, the purification 
of the most active compounds does not lead to a strong increase of IGABA modulation when 
comparing the amount of extract and the concentration of pure compounds used in the 
screening, i.e. 170 vs. 250 %. When re-calculating, 100 µg of the EtOAc extract would 
correspond to approximately 380 µM of pure effusol (250 % maximum potentiation) or even 
higher concentrations of dehydroeffusol (180 %). Moreover, both compounds were only 
tested in concentrations up to 300 µM and seemed to reach their maximum effect between 
100 and 300 µM. Several explanations are possible for such a “loss” in activity. In an extract  
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many (related) constituents can be found and although in a bioactivity-guided isolation the 
constituents mainly responsible for the observed effect are isolated, other compounds that add 
to this effect are often neglected. This could be shown for A. macrocephala, where the HPLC 
fraction containing atractylenolide I did not show promising activity when the fractions were 
screened. Atractylenolide I was nonetheless isolated due to its close structural relationship to 
atractylenolide II and III and displayed around 100 % enhancement of IGABA when applied in 
the same concentrations. Thus, although it is not as active as atractylenolide II and III, it 
probably adds to the overall activity of the extract. Moreover, when summing up the activity 
found in each of the HPLC fractions, a total of only 280 % is reached, if the negative 
(allosteric) effect of some fractions is included. This loss of activity not only points to 
additive effects probably caused by related components like atractylenolide I, but also to 
synergistic effects as well and it seems likely that compounds with low activity on the 
GABAA receptor potentiate the effects exerted by the two sesquiterpenes atractylenolide II 
and III. These additive or synergistic effects are frequently observed for herbal preparations in 
attempts to find the one compound responsible for an observed activity of a distinct extract 
(Williamson, 2001; Spinella, 2002; Houghton et al., 2007). A very good example for such 
effects is Valeriana officinalis, since it is one of the more thoroughly investigate herbal drugs. 
Valerian contains several known positive IGABA modulators from different natural compound 
classes i.e. the sesquiterpene valerenic acid (Trauner et al., 2008), the monoterpenoid borneol 
(Buchbauer et al., 1992; Granger et al., 2005) and the flavonoids linarin (Fernández et al., 
2004) and 6-methylapigenin (Wasowski et al., 2002). Additionally this herbal drug influences 
other neurotransmitter systems as well (Dietz et al., 2005; Sichardt et al., 2007). This may 
explain, why extracts and fractions are often more active compared to the isolated 
components, as it was true for all of the tested herbal drugs and once again shows, that the 
value of whole-extracts is as high or actually higher than that of single substances. Generally, 
all of the isolated compounds are highly abundant in the respective extract. It is likely, that the 
sheer amount of these substances led to their identification as the active ingredients in the 
preparations. Moreover, it is probable that many structurally related components would exert 
the same or even higher activity when isolated and applied in the same concentrations. Since 
they are contained only in traces so that their occurrence bears no meaning in a bio-activity 
guided isolation, they can not be considered the active principles. Nonetheless, such minor 
constituents surely play a crucial role in the overall IGABA modulation through the investigated 
herbal drugs.  
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Next to the discovery of the bioactivity of certain components, their use as bio-markers for 
quality control was confirmed or new markers provided. For A. macrocephala, the 
sesquiterpene lactones and for C. monnieri the coumarins imperatorin and osthole are quality-
determining markers. To the best of my knowledge, no such analytical (HPLC) method is 
available for  J. effusus. Thus, with the discovery of effusol and dehydroeffusol as GABAA 
receptor modulators, interesting marker substances for any future attempts to develop such a 
method were provided. In addition to our results, the anxiolytic activity of dehydroeffusol was 
confirmed by Liao et al. (2011) in vivo in the EPM. 
Next to minor compounds contributing to the overall activity of an extract, as discussed 
above, there could be several other reasons for the isolated substances to display lower effects 
as expected. From a study of Campbell et al. (2004), it is known that certain compounds can 
exert positive/synergistic effects when co-applied with other GABAA receptor modulators 
although they actually are antagonists, negative allosteric modulators or essentially inactive. 
This so-called “second-order modulation” was observed for epi-gallocatechin gallate (EGCG) 
and apigenin in low concentrations when co-applied with diazepam. In higher concentrations 
the antagonistic effect of apigenin and EGCG overrode their positive effect on DZP-induced 
potentiation. Considering the high potentiation reached by the C. monnieri-extract compared 
to the isolated compounds, the loss of 5/6 of the activity is very surprising. Thus several other 
components contained in the extract could influence imperatorin or osthole like EGCG or 
apigenin influence the activity of diazepam.  
Other possible reasons for such a loss in activity could be based on the methods used, either 
phytochemical or pharmacological. In general, the GABA concentration used for control and 
thus is also added to the test solution, can have great impact on IGABA modulation, since 
compounds often give higher modulations the lower the GABA concentration used. This was 
convincingly shown e.g. by Granger et al. (2005). In the present work, the initial extract 
screening was conducted with an EC1-10, while in any further studies a more confined GABA 
EC (EC5-10) was used. This would result in a significant decrease of IGABA modulation for the 
isolated substances, if the extracts were tested at lower GABA EC (EC1-5).  
In addition, fractionation on semi-preparative HPLC was conducted with water/MeCN 
gradients. By evaporating the fractions, loss of volatile components would be inevitable due 
to the evaporation of the water-portion in the fractions. This may also explain a loss of 
activity since many essential oil constituents like linalool (Hossain et al., 2007), thymol 
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(Priestley et al., 2003), or menthol (Hall et al., 2004a) are known to affect the GABAA 
receptor. However, with the HPLC methods used the volatile components are expected to 
elute with the purge phase and this phase was not included in the activity testing for neither of 
the two herbal drugs, Atractylodes and Cnidium.  Furthermore, many volatile constituents 
have already been extensively studied for their IGABA modulation effects (see chapter 1.3, pp. 
16 and 17) and thus such compounds were not studied in further detail. 
When searching for new drug scaffolds the isolation of major and minor compounds is 
essential when investigating structure activity relationships (SAR). There are several 
publications in this regard, since many groups search for IGABA modulation in a certain 
compound class with structurally related constituents. In the present thesis, such preliminary 
SAR studies were accomplished with a selection of coumarin derivatives commonly found in 
herbal drugs. During this screening compounds with mono-prenyl residues emerged as the 
only (positively) active substances. Therefore, these residues seem to be the structural features 
responsible for the activity on the GABAA receptor. Interestingly, oxypeucedanin showed a 
rather high enhancement of IGABA whereas the related heraclenin is a weak modulator of 
GABA-induced chloride currents. These two components only differ in the position of the 
epoxylated prenyl side chain and the configuration of the chiral centre. Since we found that 
the position of the side chain apparently does not interfere with the observed IGABA 
potentiation, this led us to the assumption that the differences in activity are due to the 
absolute configuration of the molecules. That such slight changes in structure can have a deep 
impact on the activity of closely related components was convincingly shown through the 
GABAA receptor activity of (+) menthol compared to five of its (inactive) stereoisomers 
(Corvalán et al., 2009). In another study, flavan-3-ols were found to exert higher activity on 
the GABAA receptor, if the 3-position is trans-configurated (Fernández et al., 2008), next to 
other activity-determining substituents (Mewett et al., 2009). This is a special trait of natural 
compounds since they - more than synthetic drugs – often posses several chiral centers and it 
again gives proof of the usefulness of components from natural origin. 
When the compounds were studied in further detail by creating a concentration response 
curve, they displayed rather moderate activity on the GABAA receptor, ranging from 100 to 
550 % IGABA potentiation. Compared to other positive GABAA receptor modulators, like the 
anesthetic etomidate, the barbiturates or some natural compounds e.g. acetyl-shengmanole 
from Actaea racemosa L. (Cicek et al., 2010), the activity of the compounds investigated 
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during this thesis is rather low. However, this does not imply that they are ineffective in vivo. 
If we consider the GABAA receptor modulators in clinical use, we know that for example the 
highly potent and efficient barbiturates enhance IGABA to a higher extent as the BZs. This 
makes the prescription of BZs not less effective but safer than barbiturates, since they can not 
be that easily overdosed. Furthermore, modulators displaying high activity in vitro and in vivo 
are more frequently used as anesthetic agents than for the treatment of insomnia or anxiety. 
Hence, the use of moderately active modulators, as is the case for many other natural 
compounds as well (Li et al., 2010b; Zaugg et al., 2010), may be more appropriate to treat 
anxiety or sleep disorders thereby probably minimizing the risk of unwanted side effects. 
Although their moderate activity might be more similar to BZs than to e.g. etomidate, none of 
the compounds studied in more detail (osthole, imperatorin, atractylenolide II, effusol and 
dehydroeffusol) did exert their activity via the BZ binding site. This was convincingly shown 
by co-application of the respective compound with the BZ antagonist flumazenil. Moreover, 
the addition of the BZ agonist diazepam - in concentrations thought to elicit maximum effects 
- to the test solution always led to a roughly additive increase in IGABA. This gives further 
evidence for a BZ binding site-independent modulation. Interestingly, many publications on 
natural compounds and the GABAA receptor use a BZ binding assay were the displacement of 
radioactively labeled BZs is measured as a determinant for the activity of natural compounds 
on the GABAA receptor, as extensively reviewed in chapter 1.3, pp. 16 - 22. For example, in a 
study of Bergendorff et al. (1997), phellopterin was found to have high affinity to the BZ 
binding site and thus considered an interesting GABAA receptor modulator. Controversially, 
in our functional screening, the same compound showed only weak effects on IGABA (~ 60 % 
potentiation at 100 µM) and the related coumarins osthole and oxypeucedanin, which 
displayed higher IGABA enhancement, revealed no dependence on the BZ binding site. 
Nonetheless, it would be possible that phellopterin is dependent on this binding site while 
oxypeucedanin is not, but due to their structural similarity this is rather unlikely. Thus, it 
seems that many of the herbal drugs screened for their “activity on the GABAA receptor”, 
revealing high affinity for the BZ binding site, are falsely considered highly potent/efficient 
GABAergic compounds. On the other hand, many such preparations could have produced 
false negative results and exert high activity on the GABAA receptor when using an 
electrophysiological approach, but on a different binding site. Such extracts would have been 
missed in an affinity screening. Thus, the two-microelectrode voltage clamp technique is 
probably more suitable for GABAA receptor activity screens. Furthermore, identification of 
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binding sites can be accomplished using electrophysiological methods, provided an antagonist 
for a certain binding site is available. In the case of the BZ-binding assay one can easily revert 
to flumazenil, as was done in the present work. Nonetheless, binding assays can give 
additional information on the binding site of a compound and some compounds with high 
affinity on the BZ binding site also displayed activity on recombinant GABAA receptors e.g. 
xenovulene A, a terpenoid structure isolated from Acremonium strictum (Thomas et al., 
1997). The independence of the investigated compounds on the BZ binding site also suggests, 
that the effect is not dependent on the γ but on α and β subunits, and thus all GABAA 
receptors in the CNS could be affected by these substances, since all of them contain α and β-
subunits. This is interesting, since αβδ-subunit containing receptor subtypes, which are in-
sensitive to the classical BZs, are responsible for tonic inhibition, providing the basic activity 
of GABAergic neurotransmission and seem to be of great importance in sleep disorders 
(Orser, 2006). Of course, the sensitivity of these receptors for the isolated compounds would 
have to be confirmed in future studies. Since the activity of our compounds seems to be 
dependent on α and/or β subunits, binding to the aforementioned extrasynaptic receptors is 
likely, unless the compounds are selective for α1 subunits, which cannot be found in 
extrasynaptic receptor subtypes. Finally, a GABAA receptor modulation without involvement 
of the BZ binding site suggests that patients under BZ treatment could profit from the intake 
of herbal remedies due to dose reduction of BZs in a combination therapy and this probably 
reduces the risk of adverse effects like dependence or tolerance. On the other hand this also 
indicates a possibility for side effects due to an over-dosage of GABAA receptor modulating 
compounds and an unwanted increase in drug activity, if the dosage is not reduced (Carrasco 
et al., 2009). However, these hypotheses would warrant further studies. Possible future work 
could also include more-detailed studies on the molecular mechanisms of the compounds on 
the GABAA receptor, i.e. determination of the binding site in binding assays or through point 
mutations and investigations for subunit specifity, to determine the probable activity in vivo 
e.g. anxiolytic, sedative or anticonvulsive. Furthermore, the compounds could be tested in for 
their ability to cross the BBB and for their metabolism in in vitro model.  Subsequently, 
“positive” findings could be confirmed in animal models e.g. EPM or rotarod test. This would 
also allow an assessment of the compounds’ toxicity. Furthermore, it would be interesting to 
unearth the discrepancy between high activity of extracts and comparably lower activity of 
isolated compounds by searching for second-order modulation or other synergistic/additive 
effects. But this would require the isolation of all components in an extract and subsequent 
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“cross-testing”, meaning co-application with the known positive modulators. In a next step, 
the investigation of the extracts in a battery of first in vitro, and then, suitable in vivo models 
would be desirable, to further confirm the synergism concept.  
Now that I determined the active principles of some CHMs, I can conclude that  
-  an ethnopharmacological approach can not only lead to the discovery of new scaffolds for 
drug development, which then could effectively be used in clinic. It, first and foremost, 
provides scientific evidence for traditional application of ethnomedicinally used drugs. Thus it 
was shown clearly in this work, that an ethnopharmacological approach is advantageous over 
a random screen. 
-  extracts are often more active as the isolated “active principles”, which clearly shows that 
extracts can have higher value than single compounds.  
-  although the isolated compounds displayed only moderate activity on the GABAA receptor, 
they can still be active in vivo, as was already shown for the phenanthrene derivatives from J. 
effusus, dehydroeffusol and effusol and the coumarin derivatives imperatorin and osthole.  
-  the two-microelectrode voltage clamp technique is more suitable as a BZ binding assay to 
screen for GABAA receptor modulators. Controversially to BZ binding assays, in which only 
the affinity of a certain compound to one of the numerous binding sites on the GABAA 
receptor is determined, the two-microelectrode voltage clamp technique offers the possibility 
to directly asses the activity of a compound on ion channels. 
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5 Summary 
 
The bioactivity guided screening of 14 different TCM herbal drugs revealed that 5 out of 
these were active when tested for their positive modulatory activity on GABAA receptors 
using of the two-microelectrode voltage clamp technique. For this purpose, 4 extracts of 
different polarity (petroleum ether, ethyl acetate, methanol and water) were produced from 
each herbal drug. 
The 3 most active drugs were chosen for further investigation: the rhizomes of Atractylodes 
macrocephala, the fruits of Cnidium monnieri and the pith of Juncus effusus. From the 
petroleum ether (PE) extract of A. macrocephala the sesquiterpene lactones atractylenolide II 
and III were isolated as the active principles by HPLC-aided fractionation giving a maximum 
enhancement of 166 ± 12 % (nH = 1.2 ± 0.1, EC50 = 70 ± 17 µM) and 157 ± 12 % (nH = 1.4 ± 
0.4, EC50 = 99 ± 20 µM), respectively. The related atractylenolide I, only differing in an 
additional double bound in position 8 and 9, enhance IGABA by “only” 96 ± 3 % (nH = 2.5 ± 
0.2, EC50 = 12 ± 1 µM).  
From the petroleum ether extract of Cnidium monnieri fruits, two compounds could be 
isolated in the same manner, revealing that the simple coumarin osthole and the 
furanocoumarin imperatorin were the compounds with strongest IGABA enhancement (124 ± 
11 % and 54 ± 13 %). To gain insights into the structural requirements of IGABA potentiation 
induced by coumarin derivatives, 16 other coumarins were investigated (100 µM). It was 
shown, that only compounds with (mono-)prenyl or -oxyprenyl residues could significantly 
enhance IGABA. From the tested compounds, oxypeucedanin showed highest maximum 
potentiation of 550 ± 17 % (EC50 = 26 ± 8 µM , nH = 1.2 ± 0.1) when applied in a 
concentration of 100 µM.  
Controversially, the Juncus ethyl acetate extract was fractionated by vacuum liquid 
chromatography followed by the subfractionation of the most active VLC fractions by 
Sephadex LH-20 column chromatography. After further purification, two compounds could 
be isolated, the phenanthrene derivatives effusol (188 ± 20 %, EC50 = 31 ± 8 µM, nH = 2.5 ± 
0.6) and dehydroeffusol (239 ± 18 %, EC50 = 27 ± 6 µM, nH = 1.4 ± 0.2).  
In summary, we isolated the “active principles” of three different CHMs. Interestingly, the 
compounds isolated belong to three different compound classes - sesquiterpene lactones, 
phenolic diterpenes and coumarins and did not display dependence on the BZ binding site.  
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6 Zusammenfassung 
Ein bioaktivitäts-geleitetes Screening von insgesamt 56 Extrakten (Petrolether, Ethylacetat, 
Methanol und Wasser) von 14 verschiedenen CHMs konnte zeigen, dass 5 dieser 
Arzneipflanzen positive modulatorische Aktivität am GABAA Rezeptor besitzen. Dazu wurde 
die Zwei-Elektroden-Spannungs-Klemm Technik verwendet. Die höchste Aktivität zeigten 
die Extrakte aus den Rhizomen von Atractylodes macrocephala, den Früchte von Cnidium 
monnieri und dem Stängelmark von Juncus effusus. Aus dem Petrolether-(PE) Extrakt  von A. 
macrocephala wurden die Sesquiterpenlaktone Atractylenolid II und III als die aktiven 
Verbindungen isoliert. Die erstellten Konzentrations-Wirkungskurven ermittelten eine 
maximale Potenzierung von 166 ± 12 % (nH = 1,2 ± 0,1; EC50 = 70 ± 17 µM) für 
Atractylenolid II und 157 ± 12 % (nH = 1,4 ± 0,4; EC50 = 99 ± 20 µM) für Atractylenolid III. 
Die strukturell ähnliche Substanz Atractylenolid I, die sich nur durch eine zusätzliche 
Doppelbindung in Position 8 und 9 unterscheidet, potenzierte IGABA nur zu maximal 96 ± 3 % 
(nH = 2,5 ± 0,2; EC50 = 12 ± 1 µM).  
Aus dem Petroletherextrakt der Früchte von Cnidium monnieri konnten auf gleiche Weise 2 
Substanzen isoliert werden. Es wurde gezeigt, dass das einfache Coumarin Osthol und das 
Furanocoumarin Imperatorin die aktiven Verbindungen darstellen (124 ± 11 % and 54 ± 13 
%). Um bessere Erkenntnisse über die strukturellen Vorraussetzungen für eine IGABA 
Potenzierung durch Coumarinderivate zu erhalten, wurden weitere 16 Coumarin-derivate 
getestet (100 µM). Es konnte gezeigt werden, dass nur Komponenten mit (mono-)prenyl oder 
-oxyprenyl Resten IGABA signifikant modulieren konnten. Von allen getesteten Substanzen 
zeigte Oxypeucedanin die höchste Wirksamkeit mit einer maximalen Potenzierung von 550 ± 
17 % (EC50 = 26 ± 8 µM, nH = 1,2 ± 0,1).  
Der Juncus Ethylacetatextrakt wurde dagegen zuerst mittels Vakuum-Flüssigchromatographie 
fraktioniert und die aktivsten Fraktionen auf Sephadex LH-20 subfraktioniert. Nach weiterer 
Aufreinigung wurden 2 Substanzen isoliert, die Phenanthrenderivate Effusol  (188 ± 20 %, 
EC50 = 31 ± 8 µM, nH = 2,5 ± 0,6) und Dehydroeffusol (239 ± 18 %, EC50 = 27 ± 6 µM, nH = 
1,4 ± 0,2).  
Letztendlich konnten die aktiven Substanzen von drei verschiedenen CHMs isoliert werden. 
Interessanterweise gehören diese zu jeweils unterschiedlichen Substanzklassen - 
Sesquiterpenlaktone, phenolische Diterpene und Coumarin, wobei keine der untersuchten 
Verbindungen Abhängigkeit von der BZ Bindungsstelle zeigte.  
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ANNEX I 
 
 
 
Atractylenolide III (19.7 mg in MeOD) 
 
 
12
1
2
3
3a
4
4a
56
7
8
8a
9
9a
10
11  
 
 
 13C  1H JH,H (Hz) 
 
2 174.5 Cq 
3 122.6 Cq 
3a 163.1 Cq 
4ax 25.6 CH2 2.41 13.2 (4eq), 12.9 (4a)/1.4 Hz (10) 
4eq   2.67  13.2 (4ax), 3.2 (5) 
4a 52.8 CH 1.91  12.9 (4ax), 3.2(4eq), 1.5(11a), 1.5 (11b) 
5 150.3 Cq 
6ax 37.2 CH2 2.02  13.4 (6eq), 13.2 (7ax), 6.0 (7eq), 1.5 (11a), 1.5 (11b) 
6eq   2.36  13.4 (6ax), 1.9 (8eq), 4.2 (7ax), 2.1 Hz (7eq) 
 
7ax 23.5 CH2 1.67  13.4 (7eq), 13.2 (8ax), 4.2 (8eq), 13.2 (6ax), 4.2 (6eq)  
7eq   1.62  13.4 (7ax), 4.6 (8ax), 2.4 (8eq), 6.0 (6ax), 2.1 (6eq)  
8ax 42.4 CH2 1.31  13.2 (8eq), 13.2 (7ax), 4.6 (7eq), 0.6 (12) 
8eq   1.54  13.2 (8ax), 4.2 (7ax), 2.4 (7eq), 1.9 (6eq)  
8a 37.8 Cq  
9ax 52.1 CH 1.48  13.4 (9eq), 0.6 (12)  
9eq   2.22  13.4 (9ax) 
9a 105.6 Cq 
10 8.1 CH3 1.79  1.4 (4ax) 
11a 17.0 CH3 4.86  1.5 (11b), 1.5 (4a), 1.5 (6ax)  
11b   4.64  1.5 (11a), 1.5 (4a), 1.5 (6ax) 
12 107.1 CH2 1.02  0.6 (9ax), 0.6 (8ax) 
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Atractylenolide II (10.22 mg in MeOD) 
 
 
12
1
2
3
3a
4
4a
56
7
8
8a
9
9a
10
11  
 
 
 13C  1H JH,H (Hz) 
 
2 177.2 Cq 
3 120.6 Cq 
3a 165.7 Cq 
4ax 26.7 CH2 2.42  13.9 (4eq), 12.8 (4a), 1.4 (9a), 1.6 (10) 
4eq   2.78  13.9 (4ax), 3.7 (4a)  
4a 51.1 CH 1.91  12.8 (4ax), 3.7 (4eq), 1.5 (11a), 1.5 (11b), 0.8 (6ax)  
5 150.1 Cq 
6ax 37.4 CH2 2.03  13.2 (6eq), 13.3 (7ax), 6.0 (7eq), 1.5 (11a), 1.5 (11b), 0.8 (4a)  
6eq   2.38  13.2, 1.6, 4.8, 2.1  
7ax 23.5 CH2 1.64 13.4 (7eq), 13.5 (8ax), 4.2 (8eq), 13.3 (6ax), 4.8 (6eq)  
7eq   1.65  13.4 (7ax), 4.4 (8ax), 2.4 (8eq), 6.0 (6ax), 2.1 (6eq)  
8ax 41.9 CH2 1.38  13.2 (8eq), 13.5 (7ax), 4.4 (7eq), 0.6 (12)  
8eq   1.58  13.2 (8ax), 4.2 (7ax), 2.4 (7eq), 1.6 (6eq)  
8a 38.0 Cq  
9ax 48.7 CH 1.10   12.0 (9eq), 11.6 (9a), 0.6 (12) 
9eq   2.28  12.0 (9ax), 6.4 (9a) 
9a 79.9 Cq 4.98  11.6 (9ax), 6.4 (9eq), 1.4 (4ax), 1.6 (10)  
10 8.1 CH3 1.79  1.6 (4ax), 1.6 (9a)  
11a 107.3 CH2 4.88  1.5 (11b), 1.5 (4a), 1.5 (6ax) 
11b   4.66 1.5 (11a), 1.5 (4a), 1.5 (6ax) 
12 16.7 CH3 0.93  0.6 (9ax), 0.6 (8ax) 
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Atractylenolide I (8.96 mg in CDCl3) 
 
 
12
1
2
3
3a
4
4a
56
7
8
8a
9
9a
10
11  
 
 
2 171.4 Cq 
3 120.5 Cq 
3a 148.3 Cq 
4 22.7 CH2 2.69 (dd, J = 17.1, 3.9 Hz, 1 H) 
   2.53 (dd, J = 17.1, 13.2 Hz, 1 H) 
4a 48.4 CH 2.37-2.32 (m, 2 H, H-4a, H-6/1) 
5 148.1 Cq 
6 36.2 CH2 2.08-2.02 (m, 1 H) 
   2.38-2.32 (m, 2 H, H-4a, H-6/1) 
 
7 23.0 CH2 1.76-1.56 (m, 2H, H-7, H-8) 
8 39.1 CH2 1.76-1.56 (m, 2H, H-7, H-8) 
8a 38.1 Cq  
9 119.2 CH 5.61 (s, 1 H) 
9a 148.0 Cq 
10 8.5 CH3 1.90 (s, 1 H) 
11 107.5 CH2 4.91 (d, J = 1.5 Hz) 
   4.62 (d, J = 1.5 Hz) 
12 18.6 CH3 0.94 (s, 1 H) 
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ANNEX IV 
 
 
 
Osthole (1.45 mg in CDCl3) 
 
 
1
2
3
45
6
7 8
9
10
11
13
12E12Z
4a
8a
CH3 C H3
OOMeO
 
 
2 161.4 Cq 
3 113.0 CH 6.24 (d, J = 9.5 Hz, 1 H) 
4 143.8 CH 7.61 (d, J = 9.2 Hz, 1 H) 
4a 113.0 Cq  
5 126.2 CH 7.29 (d, J = 8.5 Hz, 1 H) 
6 107.3 CH 6.83 (d, J = 8.6 Hz, 1 H) 
7 160.2 Cq 
8 118.0 Cq  
8a 152.8 Cq 
9 21.9 CH2 3.54 (d, J = 7.3 Hz, 1 H) 
10 121.1 CH 5.24-5.21 (m, 1 H) 
11 132.7 Cq 
12E 25.8 CH3 1.67 (s, 1 H) 
12Z 17.9 CH3 1.84 (s, 1 H) 
13 56.0 OCH3 3.92 (s, 1 H)  
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ANNEX V 
 
 
 
Imperatorin (1.86 mg in CDCl3) 
 
1
2
3
4
5
6
8
12
11
10
9
3a 4a
78a9a
13Z
13E
CH3
CH3 O
O OO
 
 
 
2 146.6 CH 7.69 (d, J = 2.2 Hz, 1 H) 
3 106.7 CH 6.81 (d, J = 2.2 Hz, 1 H) 
3a 125.8 Cq 
4 113.1 CH 7.36 (s, 1 H) 
4a 116.5 Cq 
5 144.4 CH 7.76 (d, J = 9.8 Hz, 1 H) 
6 114.7 CH 6.37 (d, J = 4.7 Hz, 1 H) 
7 160.6 Cq  
8a 144.0 Cq 
9 131.7 Cq 
9a 148.6 Cq 
10   70.2 CH2 5.01 (d, J = 6.9 Hz, 1 H) 
11 119.7 CH 5.61 (dd, J = 14.2, 6.9 Hz, 1 H) 
   5.60 (dd, J = 7.3, 7.3 Hz, 1 H) 
12 139.8 Cq 
13E 25.8 CH3 1.74 (s, 1 H) 
13Z 18.1 CH3 1.72 (s, 1 H) 
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ANNEX VI 
 
 
 
Effusol (8.62 mg in MeOD) 
 
 
1
4
4a 4b
5
6
7
8
118a
9
10
12
13
3
2
 
 
 
 
1 115.0 CH 6.63 (s, 1 H) 
2 156.4 Cq 
3 113.5 CH 6.64 (s, 1 H) 
4 137.3 Cq  
4a 127.0 Cq 
4b 127.8 Cq 
5 128.3 CH 7.18 (d, J = 8.2 Hz, 1 H) 
6 112.3 CH 6.65 (s, 1 H) 
7 155.0 Cq 
8 122.0 Cq 
8a 140.1 Cq 
9 26.6 CH2 2.68 (dd, J = 10.75, 5.7 Hz, 1 H) 
   2.66 (dd, J = 7.55; 2.5 Hz, 1 H) 
10 31.5 CH2 2.62 (dd, J = 7.25, 4.4 Hz, 1 H) 
   2.60 (dd, J = 7.9, 5.05 Hz, 1 H) 
10a 141.6 Cq 
11 11.8 CH3 2.20 (s, 1 H) 
12 140.4 CH 6.93 (dd, J = 17.35, 11.05 Hz, 1 H) 
   6.90 (dd, J = 17.35, 11.05 Hz, 1 H) 
13Z 113.5 CH2 5.63 (d, J = 17.35 Hz, 1 H) 
13E   5.19 (d, J = 10.7 Hz, 1 H) 
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Dehydroeffusol (3.40 mg in CDCl3:d6-DMSO in a ratio of 1:1) 
 
 
 
 
1
4 4a
4b
5
6
7
8
118a
9
10
12
13
3
2
 
 
 
1 110.5 CH 6.63 (s, 1 H) 
2 153.1 Cq 
3 117.5 CH 6.64 (s, 1 H) 
4 136.9 Cq  
4a 121.6 Cq 
4b 123.3 Cq 
5 124.8 CH 7.90 (d, J =9.1 Hz, 1 H) 
6 114.1 CH 6.65 (s, 1 H) 
7 151.0 Cq 
8 116.1 Cq 
8a 131.1 Cq 
9 121.9 CH 7.30 (d, J = 9.15 Hz, 1 H) 
10 125.6 CH 7.03 (d, J = 9.15 Hz, 1 H) 
10a  131.7 Cq 
11 10.0 CH3 2.05 (s, 1 H) 
12 140.4 CH 6.92 (dd, J = 17.3, 10.7 Hz, 1 H) 
   6.88 (dd, J = 17.35, 11.75 Hz, 1 H) 
13Z 112.8 CH2 4.91 (d, J = 10.7 Hz, 1 H) 
13E   5.22 (d, J = 17.0 Hz, 1 H) 
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